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Abstract 
Cytokines are proteins produced by cells of the immune system. The working 
hypothesis of the thesis is to show that the lymphocytes and glial cells in 
Glioblastoma Multiformae patients have an altered pattern of secretion of 
cytokines compared with low-grade and non-cancerous patients. Lymphocyte 
subset analysis was performed using flow cytometry. Serum specimens taken 
from both high and low grade glioma patients were analysed with samples 
taken from control patients with no history of cancer. Cerebro-spinal fluid was 
analysed from high-grade glioma patients. Comparisons of high grade pre-
surgery serum samples, high grade post-surgery samples, control pre-surgery 
samples and  control post-surgery samples were included. The analysis was 
completed utilising a luminex immunoassay. This technology is able to 
measure 34 cancer-associated analytes simultaneously. 
Immunohistochemistry of candidate biomarkers was done using primary 
tumour tissue. The results show that there were significant differences in 
several analytes in the sera and CSF of the different groups. These were 
follistatin, fibroblast growth factor (FGF),  granulocyte – colony stimulating 
factor (G-CSF), soluble human epidermal growth factor receptor 2 neural 
(sHER2neu), soluble interleukin-6 receptor alpha (sIL-6R alpha), platelet-
derived growth factor - AABB (PDGF-AABB), platelet and endothelial cell 
adhesion molecule (PECAM-1), stem cell factor (SCF), prolactin, soluble 
vascular endothelial growth factor receptor 1 (sVEGFR-1) and urokinase 
plasminogen activator (uPA). The data also show that tumour tissue revealed 
increased expression of follistatin and G-CSF with little expression of 
29 
 
prolactin. In conclusion, these results suggest that potential candidate 
biomarkers can be used to enable diagnosis of glioma and moreso to 
distinguish between different grades of glioma using a panel of biomarkers. 
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1.1 Cancer 
A cancer can be described by a group of diseases characterised by abnormal 
cell growth and a loss of control of proliferation. A tumour or neoplasm is 
usually an abnormal growth of cells that usually form a concentrated mass 
and can be either benign or malignant. A benign tumour does not spread 
(metastasise) to other parts of the body whereas a malignant tumour can 
proliferate through either local, lymphatic or haematogenous spread. A cancer 
can be defined as a malignant neoplasm with the potential to metastasise. All 
malignant tumour cells display the six hallmarks of cancer (Hanahan and 
Weinberg 2011). These include; 
 Self-sufficiency in growth signals 
 Insensitivity to anti-growth signals 
 Evasion of apoptosis (cell death) 
 Potential for limitless replication 
 The ability for sustained angiogenesis 
 Tissue invasion and metastasis 
Some authors report a seventh hallmark of cancer, that of cancer-related 
inflammation in the tumour micro-environment (Bonomi, et al. 2014). 
1.2 Glioma 
A glioma is a tumour that originates in the central nervous system (CNS), 
specifically the glial cells. Glial cells comprise the non-neuronal cells of the 
brain and spinal cord and perform specific functions. These functions include 
the stabilisation of neurones, the metabolism of neuroactive molecules, the 
control and regulation of neurotransmission and the destruction of pathogens 
32 
 
and ‘dead’ neurones. Around 50% of brain tissue is made up of glial cells with 
roughly equal numbers of neuronal cells (Azevedo, et al. 2009). Glioma cells 
can be divided into 3 types, namely, astrocytes, oligodendrocytes and 
ependymal cells. 
1.2.1 Epidemiology of glioma 
A glioma is the most common form of brain tumour. Table 1.1 provided by 
Cancer Research UK shows the incidence of all brain tumours in the UK in 
2013. The rates given are both the crude rate and the age-standardised rate 
to account for the different demographic constitution of the UK regions. This is 
done as increasing age is the most significant risk factor for getting a brain 
tumour (Ohgaki & Kleihues 2007) and enables a more accurate comparison 
between the regions.  
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Table 1.1 Number of new cases and rates of brain and other central 
nervous system (CNS) tumours, UK 2013 taken from by Cancer 
Research UK. 
 
http://www.cancerresearchuk.org/health-professional/cancer-
statistics/statistics-by-cancer-type/brain-other-cns-and-intracranial-
tumours/incidence#heading-Zero Website accessed 17/10/16 
 
 
 
England Wales Scotland Northern Ireland UK
Cases 4,312 311 464 77 5,164
Crude Rate 16.3 20.5 17.9 8.6 16.4
AS Rate 18.2 21.7 19.8 9.9 18.3
AS Rate - 95% LCL 17.7 19.3 18.0 7.7 17.8
AS Rate - 95% UCL 18.8 24.1 21.6 12.1 18.8
Cases 4,487 387 519 67 5,460
Crude Rate 16.4 24.7 18.9 7.2 16.8
AS Rate 16.9 24.0 18.9 7.8 17.2
AS Rate - 95% LCL 16.4 21.6 17.3 5.9 16.7
AS Rate - 95% UCL 17.4 26.4 20.5 9.7 17.6
Cases 8,799 698 983 144 10,624
Crude Rate 16.3 22.6 18.5 7.9 16.6
AS Rate 17.5 23.0 19.3 8.9 17.7
AS Rate - 95% LCL 17.2 21.3 18.1 7.4 17.4
AS Rate - 95% UCL 17.9 24.7 20.5 10.3 18.0
Number of New Cases, Crude and European Age-Standardised (AS) Incidence Rates per 100,000 Population, UK
Male
Female
Brain, Other CNS and Intracranial Tumours (C70-C72, C75.1-C75.3, D32-D33, D35.2-D35.4, D42-
D43, D44.3-D44.5): 2013
Persons
95% LCL and 95% UCL are the 95% lower and upper confidence limits around the AS Rate
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Within these tumour groups the glioma group makes up about half of all brain 
tumours (Table 1.2). 
Table 1.2 Incidence of brain and other CNS tumours by morphology 
taken from Cancer Research UK. 
 
http://www.cancerresearchuk.org/health-professional/cancer-
statistics/statistics-by-cancer-type/brain-other-cns-and-intracranial-
tumours/incidence#heading-Four  Website accessed 17/10/16. 
Data in the literature show that the incidence of glioma is increasing 
constantly, (Arora et, al 2010). Gliomas have the capacity to infiltrate the CNS 
and are difficult to surgically extirpate. This is one of the reasons for the high 
levels of tumour recurrence following current treatments and the associated 
patient mortality (Prados and Levin 2000). 
The World Health Organisation (WHO) produces a definitive classification and 
grading of tumours that is accepted worldwide. This is currently on its fifth 
Brain, Other CNS and Intracranial Tumours by Morphology: 2006-2010
Proportion of New Cases, England
Morphological Group
% of all Brain, other 
CNS and intracranial 
tumour cases
% of these more 
aggressive
% of these less 
aggressive
Astrocytomas 34% 95% 5%
Meningiomas 21% 8% 92%
Pituitary 8% 1-2% 98-99%
Gliomas unspecified 6% * *
Cranial and paraspinal nerve tumours 6% 5% 95%
Oligodendrogliomas 3% * *
Ependymomas 2% 75% 25%
Embryonal tumours 2% 100% 0%
Other tumour types 5% * *
Unknown or unspecified type 14% * *
* It is not possible to break down these heterogeneous groups by level of aggressiveness
35 
 
edition and was published in 2016 (Louis, et al. 2016). The classification 
criteria includes information on molecular parameters as well as histology, 
epidemiology, clinical signs and symptoms, imaging, prognosis and predictive 
factors and gives each classification an International classification of diseases 
for oncology ( ICD-O ) code, (table 1.3). 
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Table 1.3 WHO classification of tumours of the CNS taken from Louis et 
al. (2016). 
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As gliomas are primary brain tumours derived from three types of glial cells, 
namely astrocytes, oligodendrocytes and ependymal cells then for the 
purposes of this study the research focused on those gliomas from astrocytic, 
oligodendroglial, oligoastrocytic and ependymal origin. 
1.3 Glioma types 
1.3.1 Astrocytic tumours 
Astrocytes are star-shaped glial cells that perform many supporting functions 
for the neuronal cells. Tumours from an astrocytic origin are the most 
common type of brain tumour with Glioblastoma comprising 34% of malignant 
tumours of the CNS  (Cancer Research UK accessed September 2016).  
Astrocytomas can be separated into two distinct groupings. The first group 
has a circumscribed narrow zone of infiltration which include, pilocytic 
astrocytoma, subependymal giant cell astrocytoma and pleomorphic 
xanthoastrocytoma. The second group has a more diffuse zone of infiltration 
and include low grade astrocytomas, anaplastic astrocytoma and 
glioblastoma. These groupings reveal differences in cellularity, cellular 
pleomorphism, the degree of neovascularisation and the presence of necrosis 
(Desbaillets,et al. 1997). 
1.3.1. a. Diffuse astrocytoma 
These astrocytomas are slow growing tumours that frequently transform into a 
more malignant phenotype and are classified as a WHO grade II tumour.  
They are almost always fatal with median survival data ranging from 2 to 10 
years with incidence between the sexes being approximately equal. Patients 
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with these tumours are presented with changes in behaviour, language use 
and seizures. Upon histological examination these tumours show a well-
differentiated, hypercellular population of astrocytes with minimal 
pleomorphism and no mitotic activity. There is no microvascular proliferation 
and necrosis. Tumour borders are usually poorly defined with frequent 
perineuronal satellitosis (Pignatti et al. 2002). 
These tumours can be divided into three types namely: fibrillary, gemistocytic 
and protoplasmic depending on the histological appearance and each carry a 
different prognosis. Those tumours that have a significant gemistocytic 
component have a significantly poorer prognosis (Krouwer et al. 1991). 
Protoplasmic astrocytomas are histologically most frequently confused with 
fibrillary astrocytomas and they have a different incidence, being diagnosed in 
males at a younger age than in fibrillary astrocytoma (Prayson and Estes 
1995). 
1.3.1. b. Anaplastic astrocytoma 
Anaplastic astrocytomas (AA) are defined as a malignant glioma and 
classified as a WHO grade III tumour. These  are diffusely infiltrating lesions 
with focal or dispersed regions of anaplasia and marked proliferative potential 
(Arko et al. 2010) They typically display hypercellularity, cellular 
pleomorphism, nuclear atypia and microvascular proliferation. The median 
survival time ranges from 2–3 years. This is affected by the amount of time it 
takes for the tumour to progress to grade IV (Louis et al. 2007b). Anaplastic 
astrocytomas are most common between the ages of 40 to 50 years with a 
median age at diagnosis of 41. Anaplastic astrocytomas usually originate from 
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lower grade astrocytomas and transform into a malignant secondary 
glioblastoma through a series of mutations including the p53 mutation  and a 
loss of heterozygosity (LOH) on chromosome 10q and 19q (Ichimura et al. 
2004;Von Deimling et al. 1994). Figure 1.1 outlines the genetic pathways in 
the evolution of primary and secondary glioblastoma. 
 
Figure 1.1 Flow diagram showing the genetic pathways operative in the 
evolution of primary and secondary glioblastoma. Taken from Ohgaki and 
Kleihues (2007). 
 
1.3.1. c. Glioblastoma Multiforme (GBM) 
Glioblastoma multiforme is the most prevalent and malignant of all primary 
brain tumours with an incidence of about 4-5 new cases per 100,000 
population per year (Louis et al. 2016). The prognosis for such patients is 
poor with an average survival of 12 months from diagnosis (Ray-Chaudhury 
2010). This disease can occur at any age although generally it is a disease of 
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adulthood and as they are highly infiltrative they are classified as a WHO 
grade IV tumour (Louis et al. 2016). There is a slight bias towards male 
predominance (Ray-Chaudhury 2010).These tumours tend to be 
supratentorial with a diffuse infiltration into the brain parenchyma.    
The prognosis of these patients is poor. The most important prognostic factor 
is age with patients less than 50 years at diagnosis having a better prognosis 
(Louis et al. 2016). Other prognostic indicators include duration of symptoms, 
extent of resection and necrosis. (Ohgaki et al. 2006). 
1.3.2  Glioblastoma variants 
There are some cellular variants of GBMs that are also classified as WHO 
grade IV tumours. These are giant cell glioblastoma and gliosarcoma but 
these are not part of this study. 
1.3.3  Oligodendroglial tumours 
These tumours are well-differentiated, indolent neoplasms of the central 
nervous system that have a favourable prognosis. Median survival ranges 
from 6-10 years.  They are encountered less frequently than astrocytomas, 
however data suggest that they are more common than previously thought 
with estimates ranging up to 25% of primary brain tumours (Coons et al. 
1997). They can be separated into anaplastic and non-anaplastic forms. 
1.3.4  Oligodendroglioma 
These are WHO grade II tumours that originate from either oligodendrocytes 
or from glial precursor cells. They frequently demonstrate a moderate 
cellularity with rare mitotic activity. Tumour cells are diffusely infiltrating into 
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both grey and white matter with rounded nuclei giving a diagnostic ‘fried egg’ 
appearance. There is no necrosis or vascular proliferation, however, there is 
usually a network of calcified blood vessels that gives a ‘chicken wire’ 
appearance. If calcification is present then this can be a distinguishing feature 
of these tumours from astrocytomas. This can lead to spontaneous 
haemorrhage resulting in headache, confusion and lethargy as presenting 
features. The most frequent symptom of these tumours is seizures due to the 
frontal lobe involvement in 50% of cases (Jenkins et al. 2006). 
Molecular analysis of these tumours has revealed a LOH on the short arm of 
chromosome 1 (1p) and the long arm of chromosome 19 (19q) which 
correlates with improved survival (Jenkins et al. 2006). 
1.3.5  Anaplastic oligodendroglioma 
An anaplastic oligodendroglioma corresponds to a WHO grade III malignancy 
and is rarer than its less malignant oligodendroglial counterpart accounting for 
around 3.5% of malignant gliomas (Louis et al. 2016). In addition to the 
histological features of oligodendroglioma, anaplastic oligodendrogliomas may 
demonstrate areas of tumour necrosis (Louis et al. 2016). Anaplastic 
oligodendrogliomas may demonstrate an increased cellularity, cytological 
atypia, and high mitotic activity that presents as microvascular proliferation. 
Anaplastic oligodendrogliomas, in addition to the 1p and 19q chromosomal loss 
of the WHO grade II tumour also frequently demonstrate further deletions and 
genetic modifications including LOH at 10q, EGFR amplification, and 
CDKN2A/ARF deletion (Ferrer-Luna et al. 2011). There is a similar clinical 
presentation to oligodendroglioma as well as a preference for the frontal lobe. 
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1.3.6  Oligoastrocytic tumours 
Oligoastrocytomas are tumours containing varying proportions of 
oligodendrocytes and astrocytes.The astrocytes usually correspond to diffuse 
astrocytoma cells of WHO grade II. Oligoastrocytic tumours are also classified 
as WHO grade II. Previously, diagnosis was made upon the presence of 25% 
of any single cell type (Smith et al. 1983), however today any mixture of each 
tumour type can be considered an oligoastrocytoma. These tumours can, like 
oligodendrogliomas and astrocytomas, be divided into low grade and high 
grade(anaplastic) variants,  the latter characterized by increased cellularity, 
mitotic activity, microvascular proliferation and necrosis. 
1.3.7  Oligoastrocytoma 
These tumours are typically found in middle-aged patients with a small bias 
towards males. They are usually supratentorial and located in the frontal lobe 
presenting with seizures (Zhang et al. 2014).  
Prognosis is estimated at 37.6 months for anaplastic gliomas, however, due to 
the heterogenous nature of these tumours this prognosis varies between less 
than 6 months and greater than 5 years (Zhang et al. 2014). A greater prognosis 
is associated with a younger age at operation, gross total tumour resection, and 
postoperative radiation therapy (Zhang et al. 2014). It has been found that the 
greater the oligodendroglial component in such a mixed tumour, the better 
prognosis and smoother clinical course since oligodendroglial tumours tend to 
be less invasive with a greater chance of resection. The IDH-1 mutation status 
included in the Louis 2016 classification is demonstrated through the mutant 
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gene being associated with grade I and grade II tumours and rarely in 
anaplastic forms. It is also associated with younger, secondary GBMs and 
better outcomes  (Zhang 2014).  
1.3.8  Anaplastic oligoastrocytoma 
These tumours typically affect the same group of people as their low-grade 
counterparts with supratentorial lesions, also presenting with seizures. 
Histological features are also similar. Clinical outcome is inferior however with 
median survival time much shorter of 1.25 years. (Buckner et al. 2007). 
1.3.9  Ependymal tumours 
Ependymomas are tumours that derive from the ependymal lining of the 
ventricular system as well as from the central canal of the spinal cord. They 
are usually found in children and form 8-10% of paediatric CNS tumours. 
They are also present in adults where they form 1-3% of CNS tumours. In 
adults most (75%) of the tumours originate from the spinal canal. 
Histopathological features include cells from both glial and epithelial sources 
with neoplastic cells surrounding blood vessels. These are the source of the 
diagnostic perivascular pseudorosettes in which tumor cells are arranged 
around vessels with an intervening zone consisting of thin ependymal 
processes directed toward the wall of the vessel (Cotran et al. 2005). 
In tumours of spinal origin, the neurofibromin 2 gene on chromosome 22 is 
commonly mutated, however supratentorial tumours more frequently display 
mutations in chromosome 9. Ependymomas do not have mutations that are 
commonly found in other gliomas such as p53. Prognosis in these tumours is 
dependent on the extent of surgical resection and symptoms of headaches, 
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nausea and vomiting are prevalent due to the dissemination of cerebro –
spinal fluid. 
1.3.10  Anaplastic  ependymoma 
These lesions are classified as WHO grade III tumours. Histological 
classification is difficult and controversial with one study defining the presence 
of any two of four parameters as indicative of anaplastic ependymoma. These 
parameters include mitoses, hypercellularity, endothelial proliferation and 
necrosis (Ho et al. 2001). 
1.4   Glioma – Diagnosis 
Neurological signs and symptoms 
The neurological signposts most commonly associated with glioma often 
manifest over a period of weeks to months with the higher grade tumours 
presenting more rapidly than the lower grade tumours. These symptoms arise 
as a manifestation of the effect of the growing tumour on the surrounding 
tissue and include increased inter-cranial pressure, tumour invasion, 
obstructive hydrocephalus, tumour secretions or secondary cerebral ischemia. 
These initial symptoms can be nebulous and non-specific and it is not 
infrequent for there to be no presenting symptoms at all (Pace et al. 2017). 
Hence a physician needs to carefully monitor all kinds of signs and symptoms, 
however slight, to be sure that no patient is missed. A careful differential 
diagnosis must be made to be sure there are no confusions with depression, 
other causes of headaches and other neurological CNS disorders. 
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The most common symptom of a brain tumour is a headache. This is usually 
non-specific and occurs equally in patients both with and without increased 
intracranial pressure. As headache is the most common neurological 
complaint in the general population the importance of a thorough and far-
reaching differential diagnosis cannot be over-estimated. There are several 
characteristics of headaches in brain tumours that can be used to enable the 
clinician to consider an oncological pathology when engaging in diagnosis 
(Forsyth and Posner 1993). 
  These include: 
a) A daily headache on waking that rapidly improves, 
b) A new headache in a middle-aged or older person, 
c) A change in the pattern or severity of a pre-existing headache, 
d) Exacerbation of a headache by coughing, sneezing, bending, head 
movement or exertion, 
e) Headache with other neurological symptoms, 
f) Headache with vomiting, 
Aside from headaches, there are numerous other signs and symptoms 
caused by brain tumours. These include nausea, vomiting, confusion, memory 
loss and seizures and can be generalized, localizing or falsely localizing 
(Chandana, et al. 2008). 
Generalised symptoms can include dizziness and tinnitus and papilledema 
caused by an increased intracranial pressure. This can also cause vision loss, 
change in consciousness level, loss of muscle tone, itching and shivering, 
yawning and hiccups. These events are usually caused by a change in 
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position and are known as plateau waves brought on by increased intracranial 
pressure (Risberg et al. 1969). 
The most common localizing feature of brain tumours is seizure. Most patients 
with brain tumours tend to have partial seizures and they occur in around a 
quarter to a third of patients (Snyder et al. 1993). In many patients they are 
the single symptom and they are more common in low grade tumours than in 
high grade tumours. It is important to effectively differentiate those patients 
with non-convulsive epilepsy as these present in a similar manner.  
Falsely localizing signs and symptoms of brain tumours include cranial nerve 
abnormalities, ipsilateral hemiparesis and ataxia. Again, these are all signs of 
increased intracranial pressure. 
1.5 Imaging Modalities 
1.5.1 Magnetic Resonance Imaging (MRI) 
The technique of MRI is the gold standard for the imaging of brain tumours 
and gives the best anatomic detail of the brain (Figure 1.2).  It works from the 
collusion of a powerful magnetic field and a radio frequency field to give the 
protons of water molecules a specific energy or ‘spin’ that can be detected by 
scanners as a contrast between different tissues in the body. There are five 
different tissue variables that can be used to construct images. These include 
; spin density, T1 and T2 relaxation times, and flow and spectral shifts. It is 
through the manipulation of these parameters that contrast between the 
different tissue types can be obtained. The relaxation time, that is the time 
taken for the spin caused by the interaction of the fields to stop, can be 
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manipulated by specific substances known to alter these times. This property 
is also used to gain the maximum contrast between tissues. For brain 
tumours, this is most frequently done by the use of Gadolinium. The signals 
are so specific that very often the radiologist is able to predict a histological 
diagnosis. 
An adaptation of traditional MRI scanning is perfusion MRI. This imaging 
technique is used to monitor blood flow and in the case of brain tumours can 
give information about tumour vascularity and may be a reliable marker of 
tumour grade (Dhermain 2010). 
 
Figure 1.2.  T1-weighted MRI with gadolinium contrasts showing a 
typical appearance of a glioblastoma multiforme, (arrows delineate the 
site of the tumour). Taken from 
http://www.neurosurgicalassociates.com.au/index.htm accessed 12/9/17. 
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1.5.2 Magnetic Resonance Spectroscopy (MRS)  
MRS is used to measure the presence of metabolites by the analysis of 
biochemical spectra produced by the excitation of those metabolites. This can 
provide information on tumour metabolism as well as providing diagnostic 
information through the detection of specific patterns of change that correlate 
with tumour grade. For example, choline is used as a measure of cellular 
membrane turnover, creatinine as a measure of energy metabolism, myo-
inositol signifying protein C activation, lactate to measure anaerobic 
metabolism and lipid as a measure of necrosis. It is also useful in measuring a 
patient’s response to novel therapies that involve a targeted molecular 
strategy (Table 1.4). 
Table 1.4 Table showing magnetic resonance spectroscopy changes in 
brain tumours. 
High-grade tumours Low-grade tumours 
Elevated choline to N-acetyl 
aspartate ratio 
Slight increase in choline 
Decreased to absent N-acetyl 
aspartate 
Slight decrease in N-acetyl aspartate 
Decreased myo-inositol Increased myo-inositol 
Lipid present No lipid 
Lactate variable  
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1.5.3 Computerised Tomography (CT) 
Computerised tomography is an imaging technique that uses X-ray sections 
which are analysed by a computer to build a three dimensional image of the 
inside of an object from a series of two dimensional images around a central 
point of rotation.  
The advantage CT scans have over MRI scans is that it is a superior 
technique for visualising calcification. Certain tumours, such as meningiomas 
and oligodendrogliomas, present with calcification more frequently and so CT 
scanning is indicated in these cases.  CT scans are also used in assessing 
the amount of bone destruction and hyperostosis that is related to tumour 
growth. CT scans are used in brain tumour patients when there is a 
contraindication for an MRI scan (Blumenthal et al. 2015). This is usually 
because of the presence of medical or bio-stimulation implants such as 
pacemakers, vagus nerve stimulators and other ferromagnetic foreign bodies 
such as surgical prosthesis.  
1.5.4 Positron Emission Tomography (PET) 
Positron emission tomography is a nuclear medicine imaging technique that 
provides metabolic information with tumour imaging.  A radionuclide tracer is 
introduced into the body on a biologically active molecule and a positron-
detecting scanner detects the gamma rays that are emitted.  There are a 
number of different substances that can be labelled with the positron-emitting 
isotope. These include 18-fluoro-2-deoxyglucose which images glucose 
metabolism. This is the most common isotope. Other isotopes include 11-
carbon-methionine. Uptake of these isotopes in brain tumours is increased in 
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proportion with tumour grade. The tracer is phosphorylated by hexokinase 
that is abundant in tumour cells and cannot be metabolised from the tumour 
cell therefore allowing an accumulation of tracer. This means that tumour cells 
are highly labelled, a fact that becomes useful when looking for metastases or 
recurrence following resection. They are also useful in guiding stereotactic 
needle biopsies or for differentiating necrosis from recurrent tumour. They 
also have a role to play in determining response to anti-angiogenic drug 
treatments (Chen et al. 2009). 
1.5.5 Single Photon Emission Computed Tomography (SPECT) 
Single Photon Emission Computed Tomography is an imaging technique that 
involves injecting a gamma-emitting radioisotope and gaining two dimensional 
cross-sectional images of the distribution of the three dimensional isotope. 
This a more cost-effective, available imaging modality than PET that gives 
similar information. The main use of SPECT in brain tumour analysis is in 
differentiating tumour tissue from radiation necrosis. To this end it is used to 
monitor radiotherapy in brain tumour patients. 
1.6 Pathology and grading 
Although both clinical and neuro-imaging techniques are essential in the 
diagnosis of malignant glioma, a histologic examination of sample tissue 
remains the gold standard. The most accurate diagnosis is made when 
pathological studies are conducted in collaboration with a neuro-radiologist 
and a neurosurgeon with a full knowledge of a patient’s clinical history. More 
recently a molecular profile of the patient’s IDH, H3 K27M and 1p 19q deletion 
status has become incorporated into the 2016 WHO classification to give a 
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more precise definition of the tumour to aid prognosis and patient 
management (Louis et al. 2016). There is now for the first time an integrated 
diagnosis of pathology and molecular genetics. 
The most commonly applied histopathologic examination on a sampled tissue 
is the haematoxylin and eosin (H&E) stained slide. The haematoxylin stains 
the nuclei of cells a dark blue colour while cytoplasmic features are 
counterstained with eosin to produce a reddish colour. The resulting stain 
allows the histopathologist to describe microscopic morphologic features of 
the neoplasm that correlate with biological behaviour and prognosis. This has 
allowed varying grading criteria to be established, the most commonly 
accepted of which is the World Health Organisation (WHO) classification 
system (Louis et al. 2016). The system is based on the histological 
appearance of four criteria that are related to patient survival, namely nuclear 
atypia, mitoses, endothelial proliferation and necrosis.  
The WHO classification divides infiltrating gliomas, (grades II, III and IV) from 
non-infiltrating gliomas, (grade I) (Louis et al. 2016). Of the infiltrating gliomas 
these can be distinguished as astrocytomas, oligodendrogliomas and 
oligoastrocytomas based on the morphologic criteria of cell shape, 
cytoplasmic appearance and nuclei characteristics. This appearance is then 
combined with information on infiltrative capacity to give a final tumour grade. 
For example, an infiltrative astrocytoma is diagnosed when astrocytic tumour 
cells have been shown to invade CNS parenchyma. Astrocytomas in general 
have elongated nuclei that are hyperchromic and irregular and lacking in 
nucleoli and perinuclear halos (See figure 1.3).  
52 
 
A.  
B.   
Figure. 1.3 (A) A photograph showing Astrocytoma cells displaying 
elongated nuclei (arrows) compared with (B) normal brain tissue 
(taken from (A) 
http://www.microscopyu.com/galleries/pathology/images/astrocytoma40
x03.jpg on 18/7/11 and (B) original photograph. Black scale bar 
represents 20 microns. 
Gemistocytic subtypes have pink cytoplasm whilst fibrillary subtypes have 
only a minimal cytoplasm although fibrillary subtypes are not included in the 
current WHO classification. Differentiation between grade II and grade III 
subtypes is dependent upon mitotic activity. Classification of a grade III 
astrocytoma is predicated upon the appearance of more than one mitotic 
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figure that correlates with decreased survival data (Giannini et al. 1999b). The 
number of mitoses identified is reliant upon the sample size of the tissue and 
the number of sections examined. Studies have shown that the examination 
of fifty 400X field allows the detection of mitoses with 92% specificity (Coons 
and Pearl 1998). In contrast with grade II astrocytoma the grade III anaplastic 
astrocytoma has increased cellularity and proliferation as well as greater 
nuclear polymorphism and atypia. A diagnosis of glioblastoma multiforme 
(WHO Grade IV), the highest grade of infiltrating astrocytoma, is dependent 
upon the presence of microvascular hyperplasia or necrosis which is often 
pseudopalisading in addition to the previous features of astrocytoma 
mentioned (see figure 1.4. Arrows highlight the necrotic areas) 
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A.  
B.  
Figure 1.4. (A) A photograph showing GBM with arrows highlighting 
areas of pseudopalisading necrosis (Taken from wikipedia commons 
accessed 18/7/11) compared with (B) normal brain (original photograph). 
Black scale bar for A            represents 200 microns and for B represents 
20 microns.  
There is often a difficulty in differentiating high grade astrocytomas from 
oligodendrogliomas and mixed oligoastrocytomas. Oligodendroglioma cells 
have regular, spherical nuclei that display little variation from each other 
sometimes with some perinuclear cytoplasmic clearing. There is also 
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occasionally evidence of cortical involvement, calcification and branching 
capillaries (See figure 1.5)  
A.  
B.  
Figure 1.5 A photograph showing a section from a post-operative 
oligodendroglioma patient with black arrows highlighting branching 
capillaries and red arrow highlighting fried egg appearance of cells 
(Image provided by Nephron from Wikipedia commons on 18/7/11) 
compared with (B) normal brain (original photograph). Black scale bar           
represents 20 microns.    
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To differentiate between Grade II and Grade III oligodendrogliomas, attention 
must be given to the amount of vascular hyperplasia, necrosis and the 
number of mitoses present with a threshold of > 6 mitoses per high power 
field identified as the critical cut-off in survival analysis (Giannini et al. 2001). 
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Oligoastrocytomas (see figure 1.6) are comprised of distinct regions of 
oligodendroglial and astrocytic components.   
 
A.  
B.  
Fig 1.6 (A) A photograph showing a mixed glioma (anaplastic 
oligoastrocytoma) with abundant mitotic figures (black arrows) and 
nuclear pleomorphism (red arrow) (HE stain, x10 magnification), 
(provided by Jensflorin from Wikipedia Commons accessed 18/7/11 
compared with (B) normal brain (original photograph). Black scale bar           
represents 100 microns for A and 20 microns for B.   
58 
 
There has been much debate about the amount of the minimum percentage 
requirement of each component for a diagnosis to be made. A wide-ranging 
study of diagnostic criteria recommended that the presence of a single 100X 
field filled with an oligodendroglioma component could be used as a threshold 
for mixed oligoastrocytomas (Coons, et al.1997). The WHO recommendations 
describe the requirement of ‘features of anaplasia’ to be present in either the 
oligodendroglial component or the astrocytic component for a diagnosis to be 
made (Louis, et al 2016).  There is some evidence to suggest that the 
presence of necrosis in mixed oligoastrocytomas has bearing on survival and 
that those with necrosis and therefore a shortened survival expectancy should 
be classified as a grade IV tumour (Miller et al. 2006). 
Sometimes it is necessary to collect a biopsy for a frozen section diagnosis to 
guide the neurosurgeon at the time of the operation to their next course of 
action. A frozen section is a sub-optimal technique for the diagnosis of an 
infiltrating glioma. Although features such as cellular density, nuclear 
anaplasia, mitotic activity, microvascular hyperplasia and necrosis can be 
readily determined from a frozen section other distinguishing diagnostic 
features such as perinuclear halos, chromatin pattern and nuclear regularity 
are more difficult to discern with confidence.  There is also a strong possibility 
that the freezing process will introduce artefacts. These are usually 
manifested as increased hyperchromatic nuclei (Burger and Vogel 1978). 
However, most studies show a high degree of correlation (85%) between 
frozen section diagnosis and final histological diagnosis (Brainard et al. 1997).  
Immunohistochemistry can be used in brain tumour diagnosis. It is used to 
differentiate between tumour cells from GBM, metastatic carcinoma, 
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melanoma and primary CNS lymphoma (Dunbar and Yachnis 2010).  The 
distinguishing protein is glial fibrillary acidic protein (GFAP). This is a 
filamentous protein expressed by normal and malignant glial cells. There is a 
high specificity for this stain with some studies quoting 100% expression by 
the tumour cells of astrocytic neoplasms (Cosgrove et al. 1989). As well as 
being an astrocytic marker both gemistocytes and gliofibrillary 
oligodendrocytes of oligodendrogliomas have also been shown to stain for 
this marker, (Kros et al. 1990).  
O-6-methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme 
that reverses the cross-linking of DNA by chemotherapeutic agents. The 
expression level is determined by the methylation status of the MGMT gene’s 
promoter region which can silence the gene and produce a low level of protein 
expression (Riemenshneider, et al. 2010). An improved response to 
chemotherapeutic agents is linked to epigenetic silencing (Esteller 2000), 
therefore prognostic information can be obtained by testing the MGMT 
expression level of GBM patients. 
1.7 Prognosis 
There are many prognostic indicators for patients diagnosed with gliomas. This 
information comes from clinical trials and population registry data. Care must 
be taken when reviewing this data as most patients do not enter clinical trials 
and so the results may not be representative of the general population of 
patients with gliomas. This variability comes from differences within histological 
diagnoses between neuropathologists. Prognostic indicators for gliomas are 
taken from the following list: Histological diagnosis, grade of tumour, patient 
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age, patient race, patient sex, extent of resection, location of lesion, radiation 
therapy and chemotherapy taken (Curran et al. 1993 ; Davis et al. 1998). The 
single most significant prognostic factor in univariate and multivariate analyses 
has been patient age with patients less than fifty years old at the time of 
diagnosis having a better prognosis than older patients. This correlation was 
reproducible throughout the age groups in a linear fashion (Ohgaki & Kleihues 
2007) as shown using a Kaplan-Meier curve, (see figure 1.7). This is a plot of 
the survival of a group of patients, in this case, categorised into age groupings 
over a period of time. There is 100% survival at time 0, the date of diagnosis, 
and this figure, called the cumulative survival, decreases as patients die. 
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Figure 1.7. A) Kaplan-Meier curves showing that younger age of patients 
with glioblastoma is predictive for longer survival (log-rank test: <50 
years versus >50 years, P < 0.001; 50 to 59 years versus 60 to 69 years, 
P < 0.001; 60 to 69 years versus 70 to 79 years, P < 0.001; 70 to 79 years 
versus >80 years; P = 0.0261). B) On the basis of these data, formulae 
were established to calculate the median and mean survival time from 
the date of glioblastoma diagnosis (Taken from Ohgaki et al. 2007) 
Accessed 18/7/11) 
There has been a variation in response to therapy and there is a similar median 
survival across therapies. In a meta-analysis of randomised clinical trials the 
overall survival rate of high grade glioma was 40% at 1 year and 46% after 
combined radiotherapy and chemotherapy (Afra et al. 2002). The Karnofsky 
performance scale is a patient assessment tool used by clinicians to gauge a 
patient’s functional status in carrying out the activities of daily living. It is 
A) 
 
B) 
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important to continually assess patients to monitor deterioration and/or the 
effectiveness of treatment regimens (see table 1.5). There is also a strong 
correlation of survival with Karnofsky scale performance (Curran et al. 1993). 
These results may be skewed however as most clinical trials only accept 
patients with better Karnofsky scores onto their treatment regimen leaving 
those generally older patients with poorer scores with palliative treatment only.  
Table 1.5 Table showing Karnofsky performance status scale definitions 
rating (%) criteria 
Able to carry on normal activity and 
to work; no special care needed. 
  100   
Normal no complaints; no 
evidence of disease. 
90 
Able to carry on normal activity; 
minor signs or symptoms of 
disease. 
80 
Normal activity with effort; some 
signs or symptoms of disease.  
Unable to work; able to live at home 
and care for most personal needs; 
varying amount of assistance 
needed. 
70 
Cares for self; unable to carry on 
normal activity or to do active 
work. 
60 
Requires occasional assistance, 
but is able to care for most of his 
personal needs. 
50 
Requires considerable 
assistance and frequent medical 
care.  
Unable to care for self; requires 
equivalent of institutional or hospital 
care; disease may be progressing 
rapidly. 
40 
Disabled; requires special care 
and assistance. 
30 
Severely disabled; hospital 
admission is indicated although 
death not imminent. 
20 
Very sick; hospital admission 
necessary; active supportive 
treatment necessary. 
10 
Moribund; fatal processes 
progressing rapidly. 
0 Dead 
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Several studies have identified the role of the genetic changes associated 
with glioma previously mentioned and their relationship to survival although 
some such as the TP53 mutation have inconclusive data (Ohgaki & Kleihues 
2007).  
1.8 Glioma – Therapy 
1.8.1 Surgery 
Surgical intervention is essential in the therapy of brain tumours, both in the 
necessity for the collection of tissue for diagnosis, to relieve the symptoms of 
intracranial pressure and to improve outcome by maximal surgical resection. 
There is strong evidence of an  improved prognosis correlated with complete 
tumour resection (Stummer et al. 2011). This has been further improved 
following the use of techniques such as cortical mapping, stereotactic 
volumetric biopsies and resections as well as the use of robotics, lasers and 
aspirators (Arata et al. 2011). 
Before surgery commences, it is essential for the patient to undergo a 
complete pre-operative assessment using the imaging modalities of MRI and 
CT as discussed previously and also taking into account the patient’s history 
and physical examination. Magnetic resonance imaging provides information 
of tumour location and infiltration as well as the surrounding normal 
neurovascular structures. This is provided in sagittal, coronal and axial 
dimensions thereby imaging the tumour in three dimensions. Functional 
information is also provided by using the focal disturbance of cerebral blood 
flow following repetitive actions performed by the patient. This allows the 
surgeon to take into account the location of motor, sensory and language 
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cortex in relation to the tumour. Positron emission tomography scans, whilst 
not used routinely in glioma practice may be utilised preoperatively to identify 
the areas of uptake of the isotopes used guiding the biopsy to the most active 
areas. 
There are numerous devices currently available to aid in the localisation of 
tumour tissue. These include fixed frame stereotactic devices that use 
computer programs to delineate the coordinates of the area required for 
biopsy. This is augmented with ultrasound and optical microscopes that 
enable surgeons to identify areas of tumour. Post-operatively the surgeon can 
use MRI imaging to ensure a complete as possible removal of the tumour has 
taken place. Stereotactic biopsies are considered for tumours that are buried 
deep within the cerebellum or for when the patient has a serious medical 
illness. The frame is applied to the patient under a local anaesthetic. The co-
ordinates of the site are applied from information given by the MRI scan and a 
burr-hole is made and biopsy needle used to take the sample. Complications 
can arise from haemorrhage especially in vascular lesions such as 
glioblastoma. Sometimes an inadequate sample is taken and a diagnosis 
cannot be made or the diagnosis does not agree with the diagnosis from the 
full resection. Usually, the poor biopsy sample underestimates the grade of 
the tumour however diagnoses can be corrected using clinical and imaging 
information in conjunction with the biopsy (Quinn et al. 2011). Image-guided 
surgery using CT and MRI scans helps the surgeon conduct a safer and more 
successful operation (Amin et al. 2011). 
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1.8.2 Radiotherapy 
The role of radiotherapy in the treatment of any cancer is to affect actively 
dividing cells and bringing about their death through damage to DNA, cellular 
organelles and cell membranes. This generates free radicals that cause DNA 
cross links and damage to nucleotides, the cumulative effect of which is to 
induce apoptosis. This is done in order to stop the spread of the tumour 
without damaging normal tissue. In glioma therapy, a balance is sought to 
supply the maximum amount of ionising radiation to the target tissue whilst 
excluding normal brain tissue from its harmful effects. The radiation is usually 
given in fractionated doses that allow a recovery time in between. Image-
guided techniques allow for an accurate targeting of the tumour whilst 
avoiding damage to the surrounding tissue. Some factors such as cellular 
hypoxia and intrinsic cellular resistance reduce the efficacy of radiotherapy 
whilst giving radiotherapy in pulsed doses has been shown to reduce damage 
to normal brain tissue (Park et al. 2011). 
Radiation is given as a source of photons from a cobalt source and can be 
given palliatively as a single treatment or it can be given radically in a 
schedule of 25-30 treatments. Whilst it cannot ultimately cure a tumour it can 
prolong life expectancy through tumour retardation in patients suffering from 
low-grade glioma.  
External beam radiotherapy is the most commonly used technique in the 
treatment of brain tumours. Beams are directed to a specific three 
dimensional target assisted by CT and MRI imaging modalities to give a 
uniform dosage to a defined area. This treatment is then repeated multiple 
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times until the course is finished. Patient immobilisation is essential to ensure 
the correct area is treated. Greater precision can be found when using 
stereotactic radiotherapy. This involves the use of a multi-headed cobalt unit 
that can deliver radiation to a greater volume. This is known as gamma knife 
radiation therapy. There is little evidence, however, that stereotactic radiation 
offers a survival advantage over other techniques (Clavier et al. 2010). 
Another technique for delivering a dose of radiation direct to the tumour site is 
interstitial radiotherapy. This involves implanting a high dosage radioactive 
source, usually I125 or Ir192, into the tumour placed in catheters around the site 
to ensure a uniform distribution. These techniques are again as yet unproven 
(Rainov and Heidecke 2011). 
There are numerous complications to cranial radiotherapy which can be 
described as acute, early delayed or late delayed. Acute complications are 
usually associated with oedema from tissue damage and present as 
headaches and neurological deficit. Oedema is usually treated with 
corticosteroids. Early delayed complications arise from six weeks to six 
months from treatment. This is usually a neurological impairment resulting 
from demyelination of the neuronal sheath. It is a reversible phenomenon that 
can also be treated with corticosteroids. Late delayed toxicities arise years 
after radiotherapy treatment and are the result of necrosis of white matter. 
Clinically, this is indistinguishable from tumour progression and does not 
respond to treatment with corticosteroids. Demyelination is endemic as well 
as coagulative necrosis and these are diagnostic signs of radiation toxicity. 
Dementia is also sometimes an effect of radiotherapy as well as neoplasia. 
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Perversely a glioma can be induced from treatment with radiotherapy usually 
for treatment for lesions of the pituitary gland (Ron et al. 1988). 
1.8.3 Blood-brain barrier (BBB) 
The blood-brain barrier is comprised of brain capillary endothelial cells, the 
basement membrane and astrocytic feet. The endothelial cells of brain 
capillaries have sealed ‘tight junctions’ in which there are strands composed 
of trans-membrane proteins. The efficiency of the seal between the cells is 
proportional to the number of strands in the cells. The function of the BBB is 
to limit free transport of solutes between the interstitial fluid and blood. The 
endothelial monolayer of the BBB contains mechanisms of transport for 
different substances, some of which are located on the luminal side and some 
located on the abluminal side of the capillary. There are transporters for 
glucose, amino acids, vitamins and receptors that transport proteins across 
the endothelium from the direction of the blood to the brain. Toxic products 
produced by brain metabolism are transported in the reverse direction with the 
transport process beginning at the abluminal membrane (see figure 1.8). 
 
68 
 
 
Figure 1.8. Diagram showing Astrocyte–endothelial interactions at the 
blood–brain barrier (Taken from Abbott NJ et al. 2006) accessed 
21/7/11). 
The BBB is the major barrier to effective treatment of glioma with 
chemotherapeutic agents. Although some forms of glioma are associated with 
BBB breakdown the tumour cells are regularly situated away from the site of 
disruption and are therefore inadequately exposed to chemotherapy.  
Research has been undertaken to elucidate the effect of blood-brain barrier 
disruption (BBBD) on chemotherapy efficacy (Doolittle et al. 2000). Blood-
brain barrier disruption was performed by the insertion of a trans-femoral 
intra-arterial catheter into an internal carotid artery (ICA) or in a vertebral 
artery at depending on tumour location and warmed mannitol was 
administered for thirty seconds. This has the effect of osmotically opening the 
BBB allowing chemotherapeutic agents to arrive at the tumour site in a 
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greater concentration. This study showed improvements in efficacy with 79% 
of patients achieving stable disease with a low incidence of catheter related 
complications. 
Another treatment designed to circumvent BBB issues has been the use of 
biodegradable wafers impregnated with chemotherapeutic agents. The trial 
conducted by Westphal et al. (2003) found an improvement in median survival 
of 2.3 months in patients using wafers compared to those that did not. There 
were toxicities seen in the study including seizures, haemorrhages, cysts and 
wound infections. 
1.8.4 Chemotherapy 
In inducing cancer cell death chemotherapeutic agents exert their effects 
through a variety of mechanisms (see figure 1.9).  
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Figure 1.9 A figure showing both the cell-cycle dependent and 
independent mechanisms of chemotherapeutic agents. Taken from 
https://www.mycancergenome.org/content/molecular-
medicine/pathways/cytotoxic-chemotherapy-mechanisms-of-action 
accessed 21/10/2016 
Temozolomide is the most commonly prescribed chemotherapeutic agent for 
GBM and anaplastic astrocytoma (Yung 2000). It works by inducing DNA 
alkylation at multiple DNA locations producing single and double strand 
lesions. Temozolomide also suppresses MGMT levels, which reduces a 
resistance to DNA damage. Procarbazine is another alkylating agent that 
inhibits nucleic acid and protein synthesis. There are several side-effects 
connected to this treatment including rashes, nausea and vomiting. Vincristine 
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is an agent that depolymerises microtubulin formation that arrests the cell 
cycle at mitosis. It is effective with high and low grade gliomas, albeit less 
sensitive against low grade tumours, and has a neurological toxicity 
(Franceschi et al. 2017).  
1.8.5 Other treatment options 
As discussed above, the blood-brain barrier is a major obstruction for the 
delivery of chemotherapeutic drugs. Other treatment modalities are being 
explored including nanotechnology, cannabinoids, oncolytic viruses, genetic 
and molecularly targeted therapy and vaccines. Drug delivery nanosystems 
are a strategy being developed to overcome the barrier of the BBB which 
incorporate the protection of therapeutic agents, their bio-distribution and 
therapeutic index (Roger, et al. 2011).  
1.9 Cytokines 
1.9.1 General aspects 
Cytokines are specialised proteins involved in the regulation of the function of 
cells of the innate and adaptive immune system and are secreted by those 
cells in response to microbial invasion as well as other antigens. They are 
implicated in the inflammatory and immune responses by stimulating the 
growth and differentiation of lymphocytes and in the activation of cytotoxic 
effector cells. They also play an important role in haemopoiesis and are used 
clinically to stimulate or inhibit inflammation (Christofides, et al. 2015). 
Cytokines have a diverse structure, yet share many properties. They include 
the following; 
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1. Cytokine secretion is brief. There is no long-term storage of cytokines and 
synthesis is de novo through signal transduction pathways leading to 
cellular activation and gene transcription. Most cytokine mRNAs are 
inherently unstable and therefore produce a transient, short lived burst of 
cytokine production. This production is controlled by post-translational 
modification using proteolytic processing resulting in the release of an 
active product from an inactive precursor (Ehrentraut and Colgan 2012). 
2. Cytokines display the properties of pleiotropy and redundancy (Ozaki and 
Leonard 2002). Pleiotropy is the effect of a single cytokine on more than 
one cell type and is a disadvantage when considering therapeutic use as 
the number of unwanted side effects could be unmanageable. 
Redundancy is the property of multiple cytokines having the same effect 
and this also has therapeutic implications as the antagonist of one 
cytokine can be circumvented by others. 
3. Cytokines can stimulate or antagonise the production of other cytokines. 
This can lead to an over production through a cytokine cascade or it could 
lead to the mutual antagonism of different cytokines to cancel each other 
out making  a measured and predictable response difficult to achieve. 
4. Cytokines can act in an autocrine (same cell), paracrine (nearby cell) or 
endocrine (distant from site of production) fashion. Some cytokines have 
both local and systemic effects, eg. Tumour necrosis factor (TNF) 
(Locksley et al. 2001). 
5. Cytokines act as ligands and bind to cell receptors with great affinity 
usually having a dissociation constant greater than the antibody-antigen 
dissociation constant. This impacts on cytokine and cytokine receptor 
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production by requiring only a small amount of cytokine to exert its effect 
on cells. 
6. Cytokine receptors are expressed by signals from the external 
environment which influences the rate of response of those cells to the 
specific cytokine. Therefore, there is a tendency for stimulated B and T 
cells of the adaptive immune system to increase the expression of 
cytokine receptors thereby retaining the specificity of the immune 
response. This does not indicate however that the cytokines themselves 
are specific and the same receptor can be likewise blocked by the ligand 
providing a negative feedback loop as well as a positive amplification loop. 
7. The change in gene expression of the target cells usually imparts a new 
function on the target cell. Examples of this include the isotype switching 
function in B cells and the production of TH1 and TH2 subsets in helper T 
cells. Some cytokines such as TNF induces apoptosis without gene 
transcription and others called chemokines affect chemotaxis through 
changes in cellular adhesion molecule production. 
8. There are feedback mechanisms that inhibit cytokine production and they 
serve to regulate cellular responses which involve the stimulation of genes 
that code for inhibitors of the receptors or the downstream signalling 
pathways activated by the receptors. These include decoy receptors, 
kinase inhibitors and transcription factor inhibitors (O'Shea and Murray 
2008). 
Cytokines can be classified into groups according to function (Abbas 2010). 
These are as mediators of the innate immune system, mediators of the 
adaptive immune system and as mediators of haemopoiesis. The cytokines of 
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the innate and adaptive immune system are generally produced by different 
cells but the distinction is not absolute and overlapping of function does occur. 
The regulatory cytokines of the innate immune system are derived from 
mononuclear phagocytes when responding to infection. Binding occurs on toll-
like receptors (TLRs) to molecules derived from pathogens such as bacterial 
lipopolysaccharide (LPS) and dsRNA from viruses. These can be either cell 
surface receptors or in the endosomes of macrophages. Cytokines derived in 
this way include TNF, IL-1, IL-12 and IFN-γ. These cytokines can also be 
secreted by T-cell stimulated macrophages. These cytokines act on 
endothelial cells and leukocytes to stimulate the inflammatory response. 
The regulatory cytokines of the adaptive immune system are derived from T-
lymphocytes responding to the specific recognition of antigen. These 
cytokines include IL-2, IL-4, IL-5 and IFN-γ. They are implicated in the 
regulation of lymphocyte maturation and growth and thus have an intrinsic 
role in the activation of T-cell-dependent immune responses. Other cytokines 
derived from T-cells are involved in the recruitment and activation of 
neutrophils and eosinophils. These enable the activation of foreign antigen 
elimination (Nemeth and Mocsai 2016). 
All cytokine receptors (see figure 1.11) have a trans-membrane protein via 
which external ligand binding and internal signal transduction and gene 
transcription take place. The signalling pathways are usually initiated by the 
juxtaposition of the cytoplasmic domains of receptor molecules. Cytokine 
receptors are classified according to structural homologies of their extra-
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cellular domains and the intracellular signal transduction pathways and can be 
divided into families.  
Type 1 receptors contain at least one domain with two conserved pairs of 
cysteine residues and a membrane proximal sequence of tryptophan-serine-
X-tryptophan-serine (WSXWS) in which X is degenerate. These are the 
receptors that bind type 1 cytokines in which the cytokines tertiary structure 
consists of four α-helical strands. The specificity of individual cytokine binding 
is maintained by the variable amino acid residues in the receptor. The 
receptors usually differ in the ligand binding chains and share the signal 
transduction chain. All type 1 receptors use the Jak-STAT signal transduction 
pathway. Type II receptors do not have the WSXWS, use the Jak-STAT 
pathway and have a single polypeptide binding chain and a single signal 
transduction chain (Schwartz and Bonelli et al. 2016).  
The toll-like receptor is a feature of the interleukin-1 family of receptors and is 
also called the IL-1 receptor. This utilises the Interleukin-1 receptor – 
associated kinase (IRAK) family of kinases to induce gene transcription. The 
cytokines that utilise this family of receptors include IL-1 and IL-18. The TNF 
receptor family consists of proteins that have conserved trimeric cysteine-rich 
extracellular domains and utilise either the TNF receptor associated factor 
(TRAF) to activate gene transcription or the ‘death domain’ family adapter 
(FADD) to induce apoptosis (Baker and Reddy 1996). 
Seven-trans-membrane α-helical receptors cross the membrane several times 
are sometimes called G-receptors because they utilise guanine triphosphate 
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(GTP) binding proteins. These are chemokine receptors and are involved in 
chemotaxis and other inflammatory responses. 
  
Figure 1.10 Diagram showing the structure of cytokine receptors (Taken 
from Hanel et al. 2013). 
Cell-mediated immunity (CMI) serves as part of the adaptive immune system 
and is an effector function of T-lymphocytes in action against invading 
organisms that reside and reproduce inside host phagocytes. Mosmann et al. 
(1986) developed a model of CD4+ T helper cells divided into two subsets 
called Th1 and Th2 based on the expression of cytokines as well as helper 
function. Later experiments described by Coffman (2006) showed Th1 cells 
secreting IL-2, IL-3, TNF-α and IFN-γ whilst Th2 cells secreted mainly IL-4, IL-
5 and IL-13. This differentiation was also associated with function with the Th1 
cytokines controlling cell-mediated functions like macrophage activation and 
Th2 cytokines stimulating humoral immunity by activating B-cells and initiating 
class switching. Th1 differentiation usually occurs as a response to 
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marcophages affecting microbes and those that activate natural killer T cells. 
Th2 differentiation occurs in response to infection by parasitic organisms such 
as helminths as well as allergens that cause little macrophage activation. A 
further function of the differentiated Th subtype is the ability to reinforce the 
production and expansion of that subtype and the ability to inhibit the 
production of the other subtype. Each Th subset therefore can produce an 
individual effector function for any particular immunogen and can be divided 
into proinflammatory (Th1) or anti-inflammatory (Th2) responses (see figure 
1.12). 
 
Figure 1.11. Diagram showing the development of lymphocyte subsets 
(Taken from Rang, 2003). 
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In figure 1.12 an antigen is ingested and processed by an antigen presenting 
cell (APC) such as a macrophage with the peptide antigen being presented on 
the surface of the cell via the multi-histocompatibility complex (MHC). 
Lymphocytes are initially differentiated into their subtypes (CD4 positive or 
CD8 positive) by cytokine release from APCs such as macrophages and 
dendritic cells. Although these cells are normally part of the innate immune 
system, they connect to the adaptive immune system by secreting the specific 
cytokines that will trigger differentiation towards a Th1 or Th2 response. 
Yoshimoto et al. (1998) demonstrated that proteins obtained from the APC 
such as IL-12 and IL-18 are involved in the development of a Th1 cell 
response, which is self-perpetuating because these cytokines up-regulate 
their reciprocal receptors on other Th1 cells. Th2 differentiation is through IL-4 
after the naïve CD4+ T cell has bound to APCs.  
1.9.2 Role of cytokines in immune surveillance in cancer 
Cytokines play an important biochemical and physiological role in modulating 
the immune responses to tumour growth and development. They can 
influence the growth and spread of tumours through the recruitment of pro-
inflammatory cell types that can also affect angiogenesis. They can also act 
more directly by promoting or inhibiting tumour cell growth. The monitoring 
and editing of the tumour by the immune system is termed tumour immune 
surveillance (TIS) and the evasion by the tumour of an immune response is 
termed tumour immune escape (TIE). Cytokines have variable effects and 
influence in tumourigenesis and growth (Libetta, et al. 2016 ; Mullen and 
Gonzalez-Perez 2016). 
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Interferon gamma (IFN-γ) is an essential cytokine in promoting a formidable 
anti-tumour response. This cytokine plays both a protective role as well as a 
pathologic role (Boehm et al. 1997). The IFN-γ receptor is ubiquitous and 
interacts with the cytokine after being produced by natural killer (NK) cells 
initially and later by CD4+ and CD8+ T cells. This means that IFN-γ is 
involved in both innate and adaptive immune responses and has roles in the 
production of Th1 responses, cytotoxic T cell responses and in the activation 
of macrophages. Mice lacking the IFN-γ receptor subunit 1 have 20 times 
more sensitivity towards developing tumours  (Bach et al. 1997). Endogenous 
IFN-γ also protects the host from de novo tumour formation and acts 
alongside granulocyte macrophage-colony stimulating factor (GM-CSF) and 
IL-12 in tumour immune responses (Ikeda et al. 2002). 
IL-12 is secreted from APCs and it demonstrates anti-angiogenic activity 
when acting with IFN-γ by up-regulating MHC class I and II expression on 
tumour cells as well as the activation of NK cells, CD8+ CTL and the 
production of interferon-inducible protein 10 (IP-10) (Nastala et al. 1994). It 
has a significant anti-tumour response towards experimental as well as 
spontaneous metastases (Mu et al. 1995). 
GM-CSF has been shown to increase cell-specific cytotoxicity towards 
autologous tumour targets (Soiffer et al. 2003).This cytokine is usually 
involved in haemopoietic progenitor growth and differentiation yet it also has a 
role in the maintenance of a durable and powerful specific anti-tumour 
immune response. 
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The inflammatory response of neutrophils and other leucocytes have been 
implicated in the modulation of the anti-tumour response. There has been a 
link between inflammation and cancer whereby inflammatory components are 
involved in tumour promotion through their ability to respond to factors that 
support angiogenesis, tumour growth and tissue remodelling (Demaria et al. 
2010).  
Tumour necrosis factor-α (TNF-α) is produced by macrophages but also by 
tumour cells and it has a role in tissue destruction, recovery and remodelling. 
This cytokine displays both pro-and anti-tumour properties in that on the one 
hand it can cause necrosis in tumours, but then it also induces nuclear factor 
– κβ (NF-κβ) which is involved in anti-apoptotic activity (Balkwill and Joffroy 
2010). TNF-α can also inhibit DNA repair and induce angiogenic factors. 
These schizophrenic roles could be explained by the great diversity found in 
the TNF receptor complexes that stimulate different transduction pathways. 
Interleukin-6 (IL-6) displays pro-tumour properties. It has been shown to be 
involved in the stimulation of tumour growth and metastasis (Chen et al. 
2016). Other cytokines such as IL-10 and transforming growth factor-β (TGF-
β) are immunosuppressive cytokines that regulate effector responses through 
various different ways. 
The tumour microenvironment contains many soluble components that 
contribute to local immunosuppression and evasion. Transforming growth 
factor – beta (TGF-β) is a major immunosuppressant that binds to cell surface 
receptors to form a heterodimeric complex comprised of two pairs of subunits 
type I and type II. This binding elicits downstream regulation of TGF-β 
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dependent gene expression. The role of this gene has been demonstrated by 
Letterio and Roberts (1998) as one of the suppression of T-cell immune 
responses. Mice deficient in TGF-β receptors display a gross inflammatory 
response resulting in death within 3-4 weeks with an aberrant expression of 
MHC class I and II antigens. This suppression may come from TGF-β 
expression and secretion by regulatory T cells (Tregs). These cells secrete 
increased levels of TGF-β and are involved in immunological homeostasis. 
Treg cells are CD4+ CD25+ Foxp3+ cells and comprise around 5-10% of 
circulating peripheral T lymphocytes (Nishimura et al. 2004). It has been 
shown that Foxp3+ expression and suppressive activity and the size of the 
Treg cell compartment respond to signals initiated by TGF-β. These Treg 
cells, amongst others, are condensed in the tumour micro-environment 
thereby suppressing immune responses to tumour growth (Lopez et al. 2006) 
and are numerically increased in different cancers (Nomura and Sakaguchi 
2005). 
Interleukin-10 (IL-10) is a cytokine that is produced by T-cells, B-cells, 
monocytes and macrophages. It has been shown to have both 
immunosuppressant and immunostimulatory effects (Singh et al. 2015). It can 
inhibit cytokine production by Th1 cells in response to APCs as well as 
blocking the production of co-stimulatory molecules such as CD80 and CD86. 
This has the effect of limiting the strength of immune cell activation (Salazar-
Onfray 1999). The mechanism for such action is thought to be due, in part, to 
the inhibition of the maturation of dendritic cells and the subsequent down-
regulation of their capacity to initiate a Th1 response. Moreover it has also 
been shown to be the only cytokine that has an inhibitory effect on MHC class  
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I antigen presentation leading researchers to veer towards its role as an 
immunosuppressant as its primary function. Assi et al. (2014) have 
demonstrated the effect of IL-10 in antigen presentation is associated with a 
corresponding increase in MHC class II presentation. Along with its inhibition 
of pro-inflammatory cytokines such as IL-2, IFN-γ in both lymphocytes and 
monocytes, it has also been described as present in a wide range of tumour 
biopsies such as melanoma, renal carcinoma and ovarian tumours as well as 
metastatic tumours. 
Prolactin has been traditionally associated with mammary development and 
lactation. However, more recently several studies have implicated the 
hormone in tumourigenesis through disruption of the JAK-STAT pathway 
(Gorvin 2015). and its receptor in glioblastoma is being elucidated. Studies 
have detected the presence of intracellular prolactin, prolactin receptor 
(PRL-R) and hyperprolactinemia in different types of central nervous 
system (CNS) tumours. Van Meir,et al.(1990);Ciccarelli,et 
al.(2001)  discovered the presence of PRL-R and hyperprolactinemia in 
45.4% and 27.2% of meningiomas and 69.2% and 61.5% of schwannomas, 
respectively. In these studies the level of the receptor and the ligand were 
not correlated. Soares et al. (2007) discovered the presence of PRL-R in 
39% of patients with CNS tumours and the presence of intracellular 
prolactin in 21.9% of those patients. There was also hyperprolactinaemia 
in 30% of 82 cases. Their data suggested a positive correlation with 
serum prolactin and intracellular prolactin. The study analysed 12 high 
grade, 6 low grade and 6 non-cancerous specimens. The stained specimens 
were graded as 1, 2 or 3 according to the intensity of staining in the nucleus, 
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cytoplasm or interstices using the scoring system outlined in chapter 2, 
section 2.4.  
Leptin is a cytokine produced by adipocytes and it is associated with the 
satiety function and appetite regulation through interaction with the 
hypothalamus, (Zhang, et al. 1995). Leptin has also been demonstrated to 
influence cellular proliferation as well as involvement in the suppression of 
apoptosis in cells of breast, colorectal, prostate, pancreatic, ovarian and lung 
cancers (Garofalo and Surmacz 2006). All these cancers demonstrated 
increased serum levels of leptin. There have been no studies to date showing 
an increased serum level of leptin correlated with glioma malignancy, a finding 
supported by this study. Nevertheless, Leptin has been shown to enable 
tumourigenesis, angiogenesis and metastasis in these cancers (Zhou, et al. 
2011) through the stimulation of the angiogenic factor VEGF (Ferla, et al. 
2011) and an investigation into its expression in high and low grade glioma 
tissue is warranted. Riolfi, et al. (2010) found a highly significant correlation 
between the expression of leptin and its receptor ObR and the degree of 
tumour malignancy. Decreased expression of both markers was found in low 
grade astrocytomas and gangliogliomas compared with high grade anaplastic 
astrocytomas and glioblastomas. Morash, et al. (2000) reports expression of 
the Leptin gene and ObR in the C6 rat glioblastoma cell line and found that 
leptin was absent in the cytoplasm of the C6 cells, but was present in the 
nucleus. There has since been a limited amount of evidence to support this 
finding. 
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1.9.3 Role of cytokines in glioma 
The first evidence for the secretion of protein from glioma cells was reported 
in 1984 by Fontana et al. (1984). This was a factor produced from a glioma 
cell culture that inhibited T cell proliferation and function following induction 
with IL-2. It was shown that this factor was an isoform of TGF-β which as well 
as suppression of T-cells and monocytes has been implicated in the formation 
of Tregs as described above.  Further studies have demonstrated an in vivo 
role for TGF-β (Th3 cytokines) through immunohistochemical analysis. This 
study has shown that areas of tumour with greater TGF-β concentrations are 
negatively correlated with a lower number of infiltrating lymphocytes (Horst et 
al. 1992). However, blood serum levels of TGF-β have shown no difference 
between GBM patients and normal controls (Krzyszkowski et al. 2008). 
Recent work has highlighted the role of cyclo-oxygenase type 2 (COX-2) 
expression in glioma which with a secondary induction of IL-10 from dendritic 
cells has resulted in the generation of Treg cells (Akasaki et al. 2004). Some 
authors report that rather than IL-10 being secreted from glioma cells, it is 
instead restricted to circulating monocytes and infiltrating macrophages 
(Samaras et al. 2007). Monocyte cultures can be functionally manipulated by 
the down-regulation of IL-12 and a concomitant increase in IL-10 production 
by secreted factors from cultured glioma cells (Zou et al. 1999a). A subset of 
monocyte cells has been found to suppress CD4+ and CD8+ T cells (Ostrand-
Rosenberg and Sinha 2009) and is termed myeloid-derived suppressor cells 
(MDSC). These cells are able to pass through the blood-brain barrier into the 
tumour microenvironment and may be the source of systemic 
immunosuppression in GBM patients.  Interestingly patients with GBM display 
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a monocytosis with increased numbers of monocytes with the MDSC 
phenotype.  
There are various mechanisms by which malignant tumour cells may alter the 
production of endogenous cytokines through interaction with exogenous 
cytokines. These mechanisms include a change in the expression of cell 
surface receptors and changes in secondary messenger systems. Malignant 
gliomas show the most change in the alteration of cell surface receptors 
(Fukuyama et al. 2007) and GBM patients most frequently express Th2 and 
Th3 cytokines (Jackson et al. 2008). The source of the Th2 cytokine 
secretion, whether from peripheral or infiltrative lymphocytes or the glioma 
cells themselves, is still not clear.  
The brain is usually thought of as an immunologically privileged site with the 
blood-brain barrier, no lymphatic drainage and reduced expression of HLA 
molecules there is opportunity for an effective immune response due to the 
expression of antigens by the glioma cells, thereby stimulating immune cells 
towards the tumour microenvironment (Yamanaka 2008). More recently, 
however, the view that the brain has no lymphatic drainage has been 
challenged by authors who have found a lymphatic vessel drainage system in 
the dura mater of mouse brains (Louveau 2015 ; Aspelund et al. 2015).  
There is evidence that cytokines play a fundamental role in the expression of 
HLA molecules on antigen-presenting cells as well as on tumour cells 
(Papaetis et al. 2008). After an immune response has occurred, the continued 
production of cytokines is required to maintain the response. For example IL-
12 promotes IFN-γ release by NK cells that channels a Th1 pro-inflammatory 
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response that supports cytotoxic T lymphocyte (CTL) function (Lemire et al. 
2017). 
Prostaglandin E2 (PGE2) is another molecule which is implicated in immune 
suppression in a paracrine fashion. It acts to down regulate Th1 cytokine 
production and up regulates Th2 cytokine production. This molecule is 
produced by the action of the cyclooxygenase enzymes that convert 
arachidonic acid to PGE2 (Echizen, et al. 2016). The increased levels of 
PGE2 stimulates angiogenesis and motility of tumour cells and 
overexpression of COX-2 is associated with increased tumour infiltration. 
Other work has demonstrated that media containing PGE2 enhances the 
immunosuppressive activities of Tregs through the induction of mature 
dendritic cells to overexpress IL-10, a potent immunosuppressive cytokine 
(Yaqub et al. 2008).  
Angiogenesis is the proliferation of novel blood vessels from ones already 
formed. It is a complex interaction of molecular signalling events that herald 
the process of basement membrane degradation, the proliferation of 
endothelial cells, the recruitment of perivascular cells and the invasion of the 
adjacent stromal space (Jansen et al. 2004). The tumour vessels are highly 
irregular unlike normal vessels with twisted and dilated vessels of various 
diameters. There are more numerous branching points and shunts and the 
vessels contain endothelial fenestre and vesicles.. The endothelial cells 
themselves display an abnormal shape with overlapping growth patterns that 
prove to be inefficient blood transporters due to the numerous leaks caused 
by such structure. It has been suggested that this is the major cause of some 
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clinical problems experienced by tumour sufferers such as brain oedema 
(Eberhard 2000). 
Cytokines and growth factors as well as enzymes and adhesion molecules 
influence the process of angiogenesis (see figure 1.13). Genetic alteration can 
lead to the overexpression of angiogenic factors as well as an hypoxia-
induced switch to pro-angiogenic factor production from anti-angiogenic 
production is generated at the very early stages of tumourigenesis. The 
signalling pathways of angiogenesis in glioblastoma are controlled mainly by 
the vascular endothelial growth factor (VEGF),  family of molecules  and 
receptors (Alitalo and Carmeliet 2002), as well as others. These include 
angiopoietin (Reiss et al. 2005), platelet derived growth factor (PDGF) (Dunn 
et al. 2000), IL-8 (Gao, et al. 2010), follistatin (Shi, et al. 2016), hepatocyte 
growth factor (HGF) (Hartmann, et al. 2016), transforming growth factor beta 
(TGF-β) (Mangani, et al. 2016) and tumour necrosis factor alpha (TNF-α) 
(Capitao and Soares 2016). 
Vascular endothelial growth factor and its receptor perform numerous 
activities when expressed in glioblastoma vasculature. It acts as a stimulator 
for the proliferation, migration and survival of endothelial cells. It is also 
involved in regulating the permeability of blood vessels facilitating the 
transport of plasma proteins. Other functions include the stimulation of nitric 
oxide synthase that results in the production of nitric oxide, a potent 
vasodilator including the stimulation of monocyte and neutrophil migration 
(Bouloumie et al. 1999).  In conditions of hypoxia transcription of VEGF-A, 
one of six homologues, is up-regulated by hypoxia-inducible factor 1 (HIF-1). 
Moreover, mRNA stability is increased and an RNA binding protein preserves 
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translation which can lead to an increased production of VEGF-A protein and 
increased expression of the receptor (VEGFR-1) contributing to glioblastoma 
angiogenesis (Goldberg and Levy 2000). Another effect of hypoxia is the 
down regulation of thrombospondin-1 expression which is a glycoprotein 
involved in the inhibition of endothelial cell division (see figure 1.13). 
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    Increase in vessel density 
    Microvascular hyperplasia 
    Necrosis with pseudopalisading 
    Vascular proliferation and permeability 
Fig 1.12 Hand drawn flow chart showing molecular events of glioblastoma 
angiogenesis adapted from (taken from Choudhury et al. 2010). 
Figure 1.13 key 
IRES – Internal ribosomal entry site, PDGF – Platelet-derived growth factor,  
VEGF – Vascular endothelial growth factor, VEGFR- VEGF receptor, Ang- Angiopoietin,  
TSP-1 – Thrombospondin-1, HGF/SF – Hepatocyte growth factor/scatter factor, 
 bFGF – Basic fibroblast growth factor. 
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There are three VEGF receptors known to influence angiogenesis and they 
include VEGFR-1, VEGFR-2 and VEGFR-3. VEGFR-1 and 2 are associated 
with tumour angiogenesis while VEGFR-3 is usually associated with 
lymphangiogenesis (Alitalo and Carmeliet 2002). VEGFR-1 and 2 are 
expressed on mature vascular endothelial cells as well as circulating bone 
marrow derived endothelial progenitor cells. VEGFR-1 has also been found 
on macrophages and pericytes. The VEGF receptors transmit signals through 
the mitogen-activated protein kinase (MAPK) pathway and are tyrosine kinase 
receptors. Upon ligation with the VEGF ligand, the receptor dimerizes and 
becomes trans-autophosphorylated. VEGF-A is secreted by the tumour which 
plays a role in the migration of endothelial progenitor cells (EPCs) and 
haemopoietic progenitor cells to the tumour leading to vascular development 
as both VEGFR-2 and VEGFR-1 are expressed by EPCs and haemopoietic 
cells, respectively. Therefore for angiogenesis to occur both VEGFR receptors 
must contribute to the recruitment of endothelial and mesenchymal cells 
(Lyden et al. 2001). 
Platelet-derived growth factor (PDGF) normally targets capillary endothelial 
cells, the smooth muscle cells of the vessel, glial cells and neuronal cells. 
PDGF also has roles in embryonic development (Andrae, Gallini et al. 2008). 
There are several isoforms that consist of dimerized A or B chains and these 
are PDGF-AA, PDGF-AB or PDGF-BB. The PDGFB molecule is up-regulated 
in hyperplastic tumour endothelial cells. This ligand can signal downstream 
transcription and up-regulation of VEGF by endothelial cells (Dunn, Heese et 
al. 2000).  
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The platelet-derived growth factor receptor beta (PDGFRβ) has been noted on 
tumour vasculature cells (Li, Xu 2016a) and as PDGF-BB can signal through 
all PDGF receptors. In turn it is able to drive tumour progression, and it has 
been noted to upregulate the production of VEGF-A – an important 
angiogenic factor (Xue, Lim et al. 2013). 
Angiopoietin belongs to a family of growth factors that act in concert with 
VEGF in promoting neovascularisation during the formation of a tumour. 
Angiopoietin-1 and angiopoietin-2  bind to a receptor tyrosine kinase on the 
endothelium called Tie-2 (see figure 1.13). Angiopoietin-1 is secreted by 
normal pericytes and stromal cells and acts in a paracrine fashion with tumour 
cells to cause the phosphorylation of the Tie-2 receptor. This results in the 
stabilisation of newly formed blood vessels from the interaction of VEGF. In 
the absence of VEGF. Angiopoietin-2 has a regressive effect on 
vascularisation and promotes endothelial cell apoptosis (Reiss et al. 2005). 
Activin A is a well-known pro-angiogenic factor that is inhibited by follistatin. 
They are both pleiotropically implicated in cellular proliferation, differentiation 
and apoptosis in both paracrine and autocrine fashion and follistatin has been 
shown to be a potent promoter of angiogenesis (Welt, Sidis et al. 2002). 
Apoptosis in glioblastoma is most frequently disturbed by the activation of 
anti-apoptopic pathways. This is usually through the perturbation of the 
P13K/Akt/mTOR signal transduction pathway. However, there are other 
regulators of apoptosis and glioblastomas which have been shown to 
overexpress Fas ligand, Bcl-2 and TGF-β2, all thought to be apoptosis 
regulators (Choi et al. 2004).  
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1.9.4 Potential use of cytokines as a biomarker 
In order to be an effective biomarker either blood plasma and/or serum 
cytokine or angiogenesis factor secretion must have both a high sensitivity 
(few false negatives) and a high specificity (few false positives). It must also 
be responsive to disease grade and progression as well as to treatment and 
interventions. Another consideration is that levels must be detectable at 
statistically significant levels using a readily available and straight forward 
analytical technique. 
 Zisakis et al. (2007) have used an ELISPOT methodology to measure Th1 
 and Th2 cytokine secretion from mononuclear cells as well as tumour cells. 
 The measured cytokines were TNF-α and IFN-γ, both Th1 cytokines, and  IL-
 4 and  IL-10 from the Th2 cytokines. The results showed that Th1 cytokines, 
 the ‘immuno-reactive’ cytokines, were reduced compared to normal controls 
 whilst the Th2 cytokine levels,  the immunosuppressive,  were ‘strongly 
 expressed’ in both lymphocytes and tumour cells. 
The study by Zisakis et al (2007) is consistent with previous work that 
demonstrates a shift from a Th1 cytokine profile towards a Th2 type cytokine 
profile in the aetiology of glioma (Hao et al. 2002). It has also been shown that 
mononuclear cells from glioma patients are less responsive to mitogenic 
stimulation of Th1 cytokines (Urbani et al. 1995). For the Th2 cytokines, the 
opposite result is obtained upon mitogenic stimulation. Zou et al. (1999b) 
detected increased amounts of IL-2 upon the stimulation of peripheral blood 
cells with Staph. aureus. Moreover, Nitta et al. (1994) demonstrated that 
glioma cells themselves secreted IL-10 thereby contributing to cytokine 
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dysregulation  in glioma. Another influence on immunosuppression is the 
secretion by tumour infiltrating lymphocytes of Th2-type cytokines (Roussel et 
al. 1996). 
There are some cytokines that have been shown to regulate both the cell 
cycle pathway and the growth factor regulated signalling pathway. Van Meir et 
al. (1990) showed that IL-6 is secreted by glioma cell lines as well as 
increased in patient’s plasma and that it corresponds to the histopathological 
grade. IL-6 is implicated in the suppression of B-cell maturation which 
contributes to the production of increased amounts of immune complexes in 
patient’s sera that are associated with a poor prognosis. There are also 
studies suggesting that IL-6 is implicated in the pathogenesis of astrocytomas. 
Weissenberger et al. (2004) demonstrated a mitogenicity in IL-6/IL-6Ra 
transgenic mice while Sayah et al. (1999) showed that complement stimulated 
astrocytoma tumour cells produced an increase in IL-6 mRNA levels. 
IL-8 is also implicated in glioma development and its production is induced by 
acute phase proteins during the inflammatory response of early tumour 
development. Desbaillets et al. (1999) suggested that hypoxia in the tumour 
cell microenvironment causes an increase in the expression of IL-8. IL-8 
induces angiogenesis by binding to the chemokine receptors CXCR1 and 
CXCR2 thereby promoting the invasion of white blood cells and their 
activation. Samaras et al. (2009) found that the expressions of both IL-6 and 
IL-8 was increased and that this correlated with increased histological 
expression of the relevant cytokines. This interesting observation suggested 
that local tumour expression may be influenced by peripheral lymphocytes 
able to penetrate the blood-brain barrier.  
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If either a direct or indirect link from peripheral secretion to tumour cell 
expression and hence, pathological progress, could be demonstrated, then 
this would make an analysis and monitoring of peripheral blood cytokine and 
angiogenic factor secretion an ideal candidate for a clinically useful biomarker. 
1.9.5 Use of cytokines in immunotherapy 
With the disappointing results of conventional treatment for malignant 
gliomas, the use of cellular immunotherapeutic treatments has attracted a lot 
of attention. The clinical trials reviewed by Vauleon et al. (2010) involved LAK 
(lymphokine-activated killer cells), alloreactive T cells and CIK (cytokine-
induced killer cells). Other studies demonstrated an ability of NK (Natural 
Killer) cells, when activated by IL-2 and IL-15, to destroy tumour cells 
(Castriconi et al. 2009). Similarly, there have been reports of clinical use of 
cytokine therapy to activate NK cells to beneficial effect (Castriconi, et al. 
2009). 
1.9.6 Anti-tumour T-cell activity 
Most studies of cellular, anti-tumour responses have focused on cytotoxic T 
cell production and the production of CD4 and CD8 positive T cells (Zhang et 
al. 2007). Tumour cells are antigenic and they can be eradicated by 
autologous T cells (Aoki et al. 2007). In addition tumour cells are able to 
generate, through the mechanism of specific genetic alterations,  many 
tumour-specific antigens to which a cytotoxic antibody can be raised (Roth et 
al. 2007). Usually, the immunologically privileged status of the brain is 
caused, amongst other things, by the endothelial tight junctions. This is given 
as the reason why high grade brain tumours are able to evade destruction by 
the host immune defence. However this view has been challenged by the 
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demonstration by Grigoriadis et al. (2005) who have shown that systemic 
immunisation with brain-specific antigens can induce an immune response. 
This immune response is somewhat counteracted by the selective nature of 
the blood-brain barrier only allowing activated T cells entry to the brain, many 
of which are immunosuppressive regulatory T cells (Tregs). In addition, they 
can contribute to the immunosuppressive microenvironment of the tumour 
caused by high levels of TGF-β. This cytokine has been found to down-
regulate the production of IL-1 and HLA (human leukocyte antigen) class II 
molecules by antigen presenting cells leading to a decreased immune 
function (Janicki et al. 2008). Other cytokines such as IFN-γ have been shown 
to facilitate an increase in expression of both HLA class I and class II cell 
surface molecules of tumour cells. However, most brain tumour patients are 
chronically immunosuppressed with poor T cell receptor signalling, poor APC 
function as well as the tumour cells being bathed by a cocktail of 
immunosuppressive cytokines and Treg cells. Hussain et al. (2006) found that 
infiltrating macrophages has the cell surface HLA molecules but did not have 
the usual co-stimulatory CD80, CD86 and CD40 molecules that are required 
for T cell activation. 
1.9.7 Immune response to glioblastoma (GBM)  
 The process of immunosurveillance in cancer involves the identification and 
destruction of nascent tumour cells by the immune system (Vesely, et al. 
2011). Mouse models have demonstrated that innate and adaptive immune 
cells, effector molecules and pathways contribute to an extrinsic tumour 
suppressor mechanism and the increased risk of cancer development 
amongst immunosuppressed and immunodeficient individuals suggesting a 
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role for the immune system in cancer avoidance (Vesely, et al. 2011). There 
are, however, a population of immunocompetent individuals that still get 
cancer. Dunn, et al. (2012)  suggested that an immune system modification 
must have occurred to generate a tumour promoting role for the immune 
system. This dual role of tumour promotion and tumour protection is termed 
immnuoediting and has three phases. These include elimination, which is the 
recognition of cancer cells by the immune system, equilibrium, in which the 
expansion of cancer cells is controlled by the immune system and escape, 
development of immunosuppressive tumour microenvironment, (Dunn, et al. 
2012).  
The brain has long been thought of as an immunologically privileged site with 
the tight junctions of endothelial cells providing a blood-brain barrier that 
prevented the infiltration of T lymphocytes into the CNS. However under the 
pathological state of a tumour the blood-brain barrier is disrupted and 
lymphocyte trafficking to the CNS increases (Goldmann, et al. 2006). Previous 
studies have also demonstrated a long-term resident population of CD8 
positive cytotoxic T cells that persist in the brain tissue following infection. 
They are able to avoid apoptosis and do not return to the circulation (Wakim, 
et al. 2012).  
CD8 positive cytotoxic T cells provide the best response immunologically 
against tumour cells and, moreover, they have the ability to recognise 
antigenic peptides through interaction with antigen-presenting cells such as 
dendritic cells (Guermonprez, et al. 2002). This anti-tumour effect is enhanced 
by the induction of T lymphocyte production by the stimulatory cytokines IL-2 
and IFN-γ secreted by CD4 positive T lymphocytes (Guermonprez, et al. 
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2002). Microglia are sessile macrophages that respond to signals caused by 
inflammation and the presence of foreign pathogens (Stoll, 1999) and are 
implicated in the promotion of glioma through the stimulation of angiogenesis 
and tumourigenesis (Brandenburg, et al. 2016). They have also been shown 
to have a role in immunosuppression through secretion of 
immunosuppressive cytokines TGF-β and IL-10 and the Fas ligand (Badie, et 
al. 2001). The Fas pathway has been shown to play a role in immune evasion 
and the Fas ligand is also produced by a sub-population of T lymphocytes, the 
natural killer (NKT) cells (Tang, et al. 2014). 
The brain tumour microenvironment is characterised by an infiltrate of 
microglia, dendritic cells, macrophages and natural killer cells as well as T 
lymphocytes. These cells are all implicated in tumour destruction through 
several different mechanisms of immunosuppression (Watters, Schartner et 
al. 2005). 
1.9.8 Mechanisms of immunosuppression 
Tregs are CD4 positive T cells that express α subunit interleukin-2 receptor 
(CD 25) and the transcription factor FoxP3 (Yomogida, et al. 2013). Previous 
studies have demonstrated that Tregs infiltrate tumour tissue by creating an 
immunosuppressant microenvironment and contribute to tumourigenesis and 
pathogenesis (Heimberger, et al. 2008). In the tumour microenvironment, 
Tregs influence the downregulation of both CD4+ and CD8+ through different 
mechanisms such as inducing an immunosuppressive phenotype by 
interaction with dendritic cells and secreting IL-10 and TGF-β blocking the 
effector T cell response (Zou, et al. 2010). 
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Tumour-associated macrophages (TAMs) are the predominant infiltrating 
leukocyte in most tumours and evidence suggests that they are implicated in 
tumor initiation, growth, and development (Quatromoni and Eruslanov 2012). 
There are different phenotypes of macrophage with tumour suppressing (M1) 
and tumour promoting (M2) activities from differential cytokine secretion. The 
M2 phenotype mechanism of immunosuppression involves the release of 
metalloproteases such as membrane type 1-matrix metalloprotease (MT1-
MMP) which has been shown to have lytic activity on cellular binding enabling 
glioma cells to invade the brain parenchyma (Markovic, et al. 2009). 
Myeloid-derived suppressor cells (MDSC) are a heterogeneous group of cells 
produced in conditions that involve an altered haemopoietic mechanism such 
as inflammation and malignancy having a strong immunosuppressive function 
through interaction with T cells (Raychaudhuri, et al. 2015). These cells utilise 
several mechanisms in the suppression of T cell function including the 
secretion of arginase I and indolamime 2,3-dioxygenase (IDO) which act to 
catabolise the essential amino acids arginine and tryptophan respectively. 
The also produce nitric oxide (NO) and immunosuppressive cytokines such as 
TGF-β which activates epithelial mesenchymal transition therefore stimulating 
migration of malignant glioma neoplastic cells (Mazzoni, et al. 2002). There is 
also an association between MDSCs and CD4+ effector memory T-cells with 
the cell surface immune checkpoint receptor programmed death -1 (PD-1). 
This receptor is expressed on the surface of CD4+ cells and the PD-1L ligand 
is upregulated on suppressive tumour-derived MDSC (Dubinski, et al. 2016). 
The secretion of immunosuppressive factors such as IL-6 and CSF-1 by 
glioma cells contributes to the Th2 response increasing its activity and 
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reducing the strength of the anti-tumour effect (Hao, Parney et al. 2002). 
Other molecules such as prostanoids, IL-10 and the COX-2 enzyme also 
contribute to the immunosuppressive tumour microenvironment (Gomez and 
Kruse 2006). These factors combine to facilitate angiogenesis and to induce 
immunosuppression through stimulating an increase in Tregs, the 
suppression of dendritic cells, natural killer cells and cytotoxic T cells (Han, et 
al. 2015). The chemokine CCL-2 is also secreted by glioma cells and is 
involved in Treg recruitment and migration (Jordan, et al. 2008). 
Hypoxia-induced angiogenesis is one of the key models for the cause of 
microvasculature with GBM. Tumour cells that outgrow endogenous blood 
supply undergo hypoxia, mediated by HIF-1α transcription. In turn this leads 
to the transcription of angiogenic factors, vascular endothelial growth factor 
(VEGF-A), Platelet-derived growth factor ligand BB (PDGF-BB) and follistatin 
(Charles, et al. 2012a). Hypoxia stimulates the STAT3 pathway which has 
been shown to play in immunosuppressive role in glioma (Li Hong, et al. 
2016). 
1.10 Summary of literature review and scope of the study 
 
It is now possible to characterise and evaluate the cytokine and angiogenesis-
associated protein secretion from the serum and CSF of patients with 
malignant glioma with regards to their potential use as a biomarker and in 
developing novel treatment options. It is now known that cytokine and growth 
factor expression is a major factor in immune suppression, (Arrieta et al. 
2002) and enhancement, but the pattern of expression in blood and brain 
tissue has never been studied to such a detailed extent before. This study 
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aims to identify potential blood markers to predict tumour recurrence following 
surgery that will be quicker and easier to perform than the current method of 
medical imaging. This will be of great utility in the diagnosis of brain tumours 
as well as in the grading of tumours. Other aims of this project are to 
investigate the immunosuppressive properties of white blood cells and to 
detect the source of a generalised immunosuppression in glioma patient. 
1.10.1 Working hypothesis and main aim:  
The main aim of this study was to investigate the lymphocytes and glial cells 
of glioblastoma multiformae patients to determine if they have an altered 
secretion of cytokines and angiogenesis associated proteins compared with 
normal patients. It is hypothesised that these can be used as prognostic 
indicators as well as providing information leading to novel treatment 
strategies. This altered secretion can be used to detect differences in glioma 
grade and to enable the clinician to predict tumour progression from low grade 
to high grade. This may impact upon treatment strategies and allow a glioma 
screening programme to be developed. 
1.10.2 Specific aims 
To perform studies in these following areas;  
Study 1 – Optimisation of techniques 
 To validate and evaluate the bioplex analyser and cell washer for measuring 
secreted cytokines and angiogenesis-associated factors in a variety of media. 
 To perform a lymphocyte viability study on the effects of cryopreservation on 
cytokine secretion to see if cryopreservation of blood samples is an option for 
the longitudinal study. This will be done by comparing cell viability measured 
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by the cell count as well as an analysis of a range of proteins associated with 
apoptosis. 
 To establish the effect of anaesthetic received by patients on the studied 
analytes 
Study 2 – Initial investigations (biomarkers) 
 To measure cytokine and angiogenesis associated proteins in GBM patient’s 
plasma before and after resection to see if there is a significant difference in 
levels. 
 To compare serum levels of 8 cytokine and 9 angiogenesis-associated  
analytes between GBM and normal control patients. 
 To perform immunohistochemical analysis of glioma and non-cancerous 
tissue sections using antibodies raised against elevated serum analytes. 
 
Study 2 – Initial investigations (immunosuppression) 
 
 To perform immunohistochemical staining on sections from GBM and normal 
control patients to confirm the presence or absence of IL-2 receptors on 
infiltrating lymphocytes before isolating CD25 positive lymphocytes from the 
plasma for culture and measurement of cytokine secretion.  
 To compare the cytokine and angiogenesis associated protein secretion of 
peripheral regulatory T-lymphocytes in glioblastoma patients with normal 
patients. 
 
Study 3 – Experimental investigations 
 
 To compare a wider range of analytes between the sera of different grades of 
glioma and normal controls. 
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 To compare a wider range of analytes between the CSF of glioma patients 
with normal controls. 
 To develop a working diagnostic model to distinguish between cancerous and 
non-cancerous sera and CSF and to distinguish between WHO low and high 
grade glioma. 
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Chapter 2  
 
Materials and Methods 
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For the following the experiments the patient cohorts used are summarised in 
table 2.1 
Table 2.1  Study cohorts, samples and demographics
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2.1 Lymphocyte viability study 
2.1.1 Patient Samples 
11 glioma patient blood samples were collected from Royal Preston Hospital 
(RPH) in EDTA tubes. The sample was aliquoted into two separate 
containers. These were stored at 4°C and -20°C. Each sample contained 1.8 
ml of blood. A density gradient medium, lymphoprep, was used to isolate the 
lymphocytes. These samples were stored at -20°C, and a cell viability 
analysis, using 0.4% (v/v) trypan blue was performed. The sample was 
pelleted and re-suspended in 10% (v/v) DMSO and RPMI 1640 media and 
placed in a cooling chamber and stored at -80°C. The cells were thawed in a 
37°C water bath and then pelleted and re-suspended in culture media. Again 
the cellular viability was analysed using 0.4% (v/v) trypan blue. A human 
tumour necrosis factor alpha (TNF-α) instant ELISA was completed for 
samples 2-11. 
2.1.2 Isolation of lymphocytes 
A volume of 500µl of Lymphoprep™ (Axis-Shield) was placed in a 1.5 ml 
microfuge tube, and 1000 µl of the blood sample was carefully placed on the 
top of the density gradient medium. The sample was centrifuged at 800 x g for 
20 minutes. A lymphocyte layer was formed between the blood sample and 
the medium which was removed. These cells were decanted into two 1.5 ml 
microfuge tubes. The first tube had an equal amount of  0.4% (v/v) trypan 
blue. 50 ul sample of this sample was used for cell counting using a 
haemocytometer. In the second tube 1 ml of PBS was added and 650 µl was 
taken into another microfuge tube for cryopreservation. The rest of the sample 
106 
 
was centrifuged at 3000 x g for 1 minute and the supernatant collected and 
stored at -20°C. This sample was used for the ELISA.  
2.1.3 Cryopreservation of Lymphocytes 
650 µl of lymphocyte and PBS solution was centrifuged at 3000 x g for 1 
minute and the supernatant discarded. The remaining pellet was then re-
suspended and stored. RPMI 1640 culture media containing 10% (v/v) foetal 
bovine serum was mixed with 10% (v/v) dimethyl sulphoxide (DMSO). 1.0 ml 
of the culture media/DMSO solution was mixed with the lymphocyte/PBS 
solution and the sample was pelleted and placed in a cooling chamber and 
stored at -80°C. The cooling chamber mediated a cooling rate of 1°C/min. The 
samples were then thawed using a 37°C water bath for 7 minutes and 
centrifuged for 1 minute at 2400 x g. The supernatant was discarded, and the 
pellet was re-suspended in 1.0 ml RPMI 1640.  
2.1.4 Human TNF-α ELISA 
A human TNF-α instant ELISA (ebioscience) kit was used to measure the 
concentration of TNF-α in the paient samples. Columns A-G, rows 1-2 of the 
microtitre plate were used for reference standards with particular amounts of 
TNF-α, (table 3.4). The kit was stored at -20°C and removed from the freezer 
on the day of use. A volume of 100 µl of distilled water was added to each 
well in the microtitre plate including the standard wells. 50 µl of sample from 
the patient samples was added to the wells. The microtitre plate was covered 
and the samples were mixed using a microplate shaker. The plate was then 
incubated for 3 hours at 22°C. 
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The plate cover was removed and the wells were washed 6 times with 400 µl 
wash buffer (PBS pH7.0 plus surfactant). Between each wash excess buffer 
was removed by tapping the plate on tissue paper. Whilst the plate was still 
wet, 100µl of tetramethyl-benzidine substrate solution was added to all wells. 
The plate was incubated for 10 minutes at 22°C. The enzyme reaction was 
stopped after 10 minutes by adding 100µl of 1.0M phosphoric acid stop 
solution into each well. A Bio-tek plate-reader was used to measure the 
absorbance of the wells. This was read at a wavelength of 450 nm. 
2.2  Presence of Tregs in high and low grade gliomas  
2.2.1 Sample Collection 
Buffy coat samples were used in this study. This is the middle fraction of 
centrifuged blood that contains platelets and white blood cells. They are 
prepared by centrifuging the blood sample at 200 x g for 10 minutes with the 
centrifuge brake off. The white layer that sits above the red blood cell fraction 
is the buffy coat and is carefully removed. The buffy coat samples were from 
the Royal Preston Hospital and consisted of glioblastoma multiforme (GBM) 
(Grade IV) and Meningioma (Grade I) patients. These were collected within 
ethical guidance and clearance from the Brain Tumour North West (BTNW) 
tissue bank. Patient demographics used for the study were taken, (see Table 
2.1), and the age ranges for the two groups were GBM, (58-85 years) and 
meningioma, (24-71 years). The volume of the buffy coat samples received 
was variable and ranged from 0.1ml to 1.5 ml. The samples were stored in a -
80°C freezer and thawed slowly at 4°C before use.  
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An Horiba ABX Pentra 60 C + haematology analyser was used to provide the 
total WBC (White Blood Count) which was used as the absolute cell number 
in the buffy coat sample. The WBC count was given as x 103 cells/mm3 . This 
was diluted to 1x106 cells/ml which is the required concentration according to 
the kit manufacturer’s instructions. The volume of samples required for this 
dilution was calculated thusly: 
Sample volume of 1x 106 cells per ml = (Total volume of sample) 
          WBC 
2.2.2 Cell thawing and Cell Viability 
Trypan blue was used to measure cell viability and the cells were counted 
using a haemocytometer. There were two methods of thawing of the sample 
taken from the -80°C freezer. Slow thawing was done using a 4°C refrigerator 
and fast thawing using a 37°C water bath.  
2.2.3 Treg Detection  
The buffy coat samples were used in the analysis of the Treg compartment 
using Miltenyi Biotec ‘Treg Detection Kit (CD4/CD25/FoxP3) (PE), human’. 
This kit comprised of surface staining antibodies: anti-CD4 (VIT4)-FITC, and 
anti-CD25-APC and the intracellular staining antibody: Anti-FoxP3-PE, FcR 
blocking reagent, fixation/permeabilization solution I, fixation/permeabilization 
Solution II, and 10X permeabilization buffer. The buffer used for the analysis 
was a solution of phosphate-buffered saline (pH 7.2), 0.5% (v/v) bovine serum 
albumin and 2mM Ethylene diamine tetra acetic acid (EDTA). 
The labelling procedure used was that provided by the manufacturer. The cell 
suspension was centrifuged at 300 x g for 10 minutes. The supernatant was 
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aspirated and 1x106 cells were re-suspended. 10 µl of anti-CD4-FITC and 10 
µl of anti-CD25-APC antibodies were added to the cell suspension and this 
was then incubated for 10 minutes at 4°C in the dark. The cells were washed 
with 1.0 ml of buffer and centrifuged at 300 x g for 5 minutes at 4°C. To 
perform the intracellular labelling cells were incubated with 1ml of a 1:4 
dilution of  fixation/permeabilization solution I and fixation/permeabilization 
solution II. This was done for 30 minutes at 4 °C in the dark. The cells were 
washed with 1X permeabilization buffer and FcR blocking reagent was used 
to prevent non-specific binding. 10 µl of Anti-FoxP3-PE were added to the 
suspension for 30 minutes at 4 °C in the dark.  The cells were then washed 
and centrifuged at 300 x g and the remaining cell pellet was re-suspended in 
400 µl buffer. 
2.2.4 Analysis of Tregs using flow cytometry 
The labelled samples were analysed using the Guava® easyCyte HT 
sampling flow cytometer. 200µl of each sample was added to the 96 well 
plate. Table 2.2 describes the excitation and emission wavelengths used for 
the set up of the flow cytometer. 
Table 2.2. Table showing flow cytometry setup. 
 
Antibody Fluorophores
Excitation 
wavelength 
(nm)
Emission 
wavelength 
(nm)
Filter 
(max/BP
)
Laser 
(Fluorescence
)
CD4
FITC (fluorescein 
isothiocyanate)
488 519 530/30 Green- Blue
CD25
APC 
(Allophycocyanin)
633 660 660/20 Red- Red
Anti-FoxP3
PE 
(Phycoerythtin)
488 578 575/26 Yellow- Blue
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2.3 Bioplex method/optimisation  
A luminex suspension array system (Biorad) was used to quantify the cytokine 
concentrations. 
The Bio-Plex system permited multiplexing of theoretically up to 100 different 
ELISA-type assays within a single sample. Each assay was performed on the 
surface of a 5.5 μm polystyrene bead. The beads were filled with different 
ratios of two different fluorescent dyes, resulting in an array of 100 distinct 
spectral addresses. Each set of beads could be conjugated with a different 
capture molecule; the conjugated beads can then be mixed and incubated 
with the sample in a microplate well to react with specific analytes. A 
fluorescently labelled reporter molecule that specifically binds to the capture 
molecule is added. Precision fluidics align the beads in a single file through a 
flow cell where two lasers excite the beads individually. The red classification 
laser excited the dyes in each bead, thereby identifying the specific bead 
address. The green reporter laser excites the reporter molecule associated 
with the bead, allowing quantitation of the captured analyte. 
A verification and calibration procedure of the luminex analyser was carried 
out according to the manufacturer’s instructions before analysis took place. 
The manufacturer supplied reagents from different kit batches which were 
used to confirm the accuracy, precision and reproducibility of the analytical 
technique used. A range of samples were tested using reagents from different 
batches and the results compared. Samples were performed in duplicate on 
the 96 well plate alongside the standard curve used to generate the results. 
Two wells with only manufacturer’s diluents were used as blanks and the 
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resultant background reading levels were subtracted from all sample results. 
One sample from a single patient was included on each plate to control for 
inter-plate reproducibility. 
2.3.1 Role of immunosuppressive cytokines  
Serum samples from 50 GBM (grade 4 glioma) patients were analysed along 
with 27 non-cancerous control patients. Sera were also analysed from 36 
patients with GBM who underwent biopsy or debulking of tumour. The sera 
were collected both immediately pre-operatively and within 24 hours of 
surgery.  
Control serum samples were also collected immediately pre and post-
operatively within 24 hours of surgery from 36 patients with no known history 
of malignancy. These patients underwent elective surgery for a non-
cancerous pathology.  
The levels of 8 cytokines and 9 angiogenesis-associated factors were 
simultaneously evaluated using the Bioplex analyser supplied by BioRad.  
The cytokines measured were IL-2, IL-4, IL-6, IL-8, IL-10, GM-CSF, INF-γ and 
TNF-α.  
The angiogenesis-associated factors were angiopoietin-2, follistatin, G-CSF, 
HGF, IL-8, leptin, PDGF-BB, PECAM-1, VEGF.  
2.4 Immunohistochemical staining of primary GBM biopsies 
Formalin-fixed, paraffin embedded tissue sections were obtained with ethical 
clearance from the Brain Tumour North West (BTNW) tissue bank at the 
University of Central Lancashire.  
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Slides were deparaffinised using two Sigma histoclear rinses followed by two 
90% ethanol rinses. Antigen retrieval was performed in citrate (pH 6) buffer in 
the pre-treatment (PT) link machine (Thermo Shandon) set at 97 °C for 40 
minutes. Residual endogenous peroxidase activity was quenched using a 
0.3% (v/v) hydrogen peroxide solution for 15 minutes. The staining procedure 
followed the manufacturer’s instructions using the Vectastain Elite ABC Kit: 
PK-7200. PBS pH 7.4 was used for the washing reagent as well as for 
antibody dilution. Horseradish peroxidase (HRP) enzyme and 3,3′-
diaminobenzidine (DAB) substrate was used to localise peroxidase activity. 
DAB was made up to manufacturer’s instructions. The slides were 
counterstained using haematoxylin for 1 minute and washed with hot tap 
water. The slides were then dehydrated using two methylated spirit and two  
Sigma histoclear rinses. The slide were then mounted for inspection by at 
least two investigators. Immunohistochemical staining was performed using 
the antibodies and dilutions in table 2.3. The optimum dilutions were 
determined by preliminary experimental staining. 
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Table 2.3 The antibodies used in the immunohistochemistry of glioma 
and non-cancerous tissue sections. 
 
A scoring system was applied to analyse the intensity of staining of the tissue 
sections (Table 2.4). 
Table 2.4. Scoring system for stained sections   
 
 
 
 
Antibody Dilution
Species/clo
nality
Supplier
Follistatin 1:250
Rabbit/ 
polyclonal
Abcam
Leptin 1:500
Rabbit/ 
polyclonal
Abcam
Prolactin 1:500
Rabbit/ 
polyclonal
Abcam
PDGF-AA 1:200
Rabbit/ 
polyclonal
Abcam
PDGF-BB 1:200
Rabbit/ 
polyclonal
Sigma
PDGFRα 1:200
Rabbit/ 
polyclonal
Sigma
PDGFRβ 1:200
Rabbit/ 
polyclonal
Sigma
0 No staining
1 Weak staining 
2
Moderate/intermediate 
staining 
3 Strong/intense staining 
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2.5 Enzyme-linked Immunoassay (ELISA) 
The samples for this study were obtained with ethical clearance from the Brain 
Tumour North West (BTNW) tissue bank at the University of Central 
Lancashire.  
The serum serum was stored at -80 °C and thawed at 22°C. 
The ELISA kits used were from Sigma Aldrich for the PDGF-BB (RAB0397) 
and PDGF- AA (RAB0394) ligands. A volume of 200 µl of each standard was 
added to the first column on an antibody coated ELISA plate. A serial dilution 
of the standard solution was made. This dilution covered 400pg/ml – 0pg for 
PDGF-BB and 30,000pg/ml – 0pg/ml for PDGF-BB.  A volume of 100 µl of 
each serum sample was added to specific wells of the ELISA microtitre plate. 
Each sample was added in duplicate. Control wells were made using all of the 
reagents with the omission of the patient samples.  The wells were covered 
and the plate was gently agitated overnight at 4°C. The wells were emptied of 
liquid and washed four times with wash buffer (PBS plus surfactant). The 
liquid was decanted after the last wash. The detection antibody was prepared 
and added to the wells of the microtitre plate. The plate was incubated for 1 
hour at 22°C with gentle agitation. The liquid was discarded and the wells 
were washed using wash buffer. HRP-Streptavidin was added to each well 
and the microtitre plate was incubated for 45 minutes at 22°C with gentle 
agitation. The liquid was discarded and the wells washed using wash buffer. A 
volume of 100 µl Colorimetric TMB reagent was added to each well and 
incubated at 22°C in the dark with gentle agitation. A volume of 50 µl of stop 
solution was added to each well and a colourimetric reaction took place within 
the wells. The microtitre plate was then read spectroscopically at 450nm in an 
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Omega 96 well plate reader. The mean absorbance for the duplicate 
standards and samples was then calculated. The absorbance from the control 
wells was subtracted from the sample wells. Myassay.com was used to plot 
the standard curves in order to determine the serum concentrations of the 
analysed molecules. 
2.6 Blood-borne biomarker study 
2.6.1 Tissue/serum collection 
Serum samples were collected from 115 patients with glioblastoma (WHO 
Grade IV) and 44 patients with ‘low grade (WHO Grade II) of which 25 were 
astrocytomas (grade II), 15 were oligodendrogliomas (grade II) and 4 were 
ependymomas (grade II) using the Louis 2007 WHO classification system. A 
total of 33 samples from patients with no history of cancer were taken from 
pre-operative clinics and from volunteers with informed consent.  Samples 
were obtained from the Walton Research Tissue Bank and the Brain Tumour 
North West tissue bank under ethical clearance no. 09/H0304/88. UCLan’s 
School of Pharmacy and Biomedical Science’s Health and safety committee 
also gave ethical approval on 22nd February 2010. Only newly diagnosed 
patients with a histopathological diagnosis of WHO Grade II and IV were 
included. The glioblastoma patients were all given a high dose, (16mg/day), of 
Dexamethasone. A total of 23 of the high grade glioma patients were treated 
with Temozolomide. The low grade glioma patients and the non-cancerous 
controls were not on any oncological medication. Informed consent was taken 
pre surgery by consultant neurosurgeons. All pre-operative high grade blood 
samples were taken in theatre whilst the patient was under anaesthetic and 
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low grade blood samples were taken in the outpatients clinic. Post-operative 
samples were taken within 24 hours of debulking. The serum tubes were left 
to clot at room temperature for a minimum of 30 minutes and a maximum of 2 
hours from blood draw to centrifugation. Separation of the clot was 
accomplished by centrifugation at 1,200 x g for 10 minutes and 500 µl aliquots 
of serum dispensed into prelabelled cryovials.  Serum samples were snap 
frozen using liquid nitrogen and stored at -80oC.   
Cerebro-Spinal Fluid (CSF) samples from 8 glioblastoma patients and 8 non 
cancerous patients were taken by Lumbar puncture at Athens Hospital. The 
samples were taken using a local anaesthetic prilocaine and were taken prior 
to surgery. The patients were not on any other medication. 
2.6.2 Clinical data collection 
The 115 glioblastoma patients comprised of 42 females (mean age 57.8 
years) and 73 males (mean age 61.5 years). The 44 low grade patients 
comprised of 21 females (mean age 48.6 years years) and 23 males (mean 
age 48.4 years). The 33 control samples comprised of 13 females (mean age 
58.1 years) and 20 males (mean age 61.7 years). Survival data from 53 
glioblastoma patients was analysed for correlation with the serum levels of all 
significantly raised biomarkers. 
2.7 Statistical analysis  
2.7.1 Statistical analysis of Treg study data 
All measurements were performed in duplicate and statistical analysis was 
performed in Microsoft Excel. The results were analysed using a two-tailed 
paired samples t-test (cell viability) and a two-tailed pearson’s correlation 
117 
 
coefficient (ELISA). The mean, standard deviation and standard error of the 
relative amount of CD4+CD25+FoxP3+ Tregs was measured for both GBM 
and meningioma groups. The differences in mean were shown using an 
histogram plot with error bars delineating the standard error. A student’s t-test 
(two-sample assuming unequal variances) was performed to compare the 
patient groups for both the analysis of Treg and serum and CSF cytokine 
levels. The statistical tests were carried out using a p<0.05 significance level.  
2.7.2 Statistical analysis of blood-borne biomarker data  
Significance between groups was measured using a paired t-test and 
correlations (study 1) and a Mann-Whitney U test assuming non-Gaussian 
distribution (studies 2, 3 and 4). The survival data was examined for 
correlation with each anylate level using the CORREL function on Microsoft 
Excel.  A P<0.05 was considered statistically significant.  Power analysis was 
performed using an online calculator (powerandsamplesize.com) on the 
significant potential biomarkers in study 2 to determine the minimum sample 
size required for 80% power using a difference of 2 standard deviations to 
distinguish between glioma and non-cancerous sera and between low and 
high grade glioma. 
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3.1 Lymphocyte viability study 
The rationale for this part of the study was to determine the effect of 
cryopreservation on lymphocytes, to determine if the method of storage had an 
effect upon cytokine secretion. 
3.1.1 Cell Viability 
Lymphocyte cell viability results for the 4°C stored samples are shown in Table 
3.1.  
Table 3.1.  The percentage viability for lymphocytes stored at 4°C using 
trypan blue. 
 
* The age of the sample is given as the number of days from collection from 
Royal Preston Hospital to testing 
The sample from patient 1 was severely haemolysed therefore there was no 
result for this sample. In this study the mean viability was 91.93% and the 
standard deviation was 5.46. 
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Lymphocyte cell viability results for the -20°C stored samples are shown in 
(Table 3.2). 
Table 3.2.  The percentage viability for lymphocytes stored at -20°C 
using trypan blue. 
 
 
 
In this study the poor results for patients 2 and 3 demonstrated that the -20°C 
storage destroyed the integrity of the cells. The cryopreservation and freezing 
protocol was performed for the rest of the study samples. Lymphocyte cell 
viability results for the -80°C stored samples are shown in Table 3.3. 
Table 3.3.  The percentage viability for lymphocytes cryopreserved and 
stored at -80°C using trypan blue. 
 
 
Patient 11 was not included in the study as this sample was a fresh sample and 
was not cryopreserved. The mean viability was 27.71% and the standard 
deviation was 16.43. 
Patient Sample No Viable Non- % 
0 897 78 6 99.3
2 900 66 12 84.6
3 901 22 112 16.4
Patient Sample No
Viable 
Cells
Non-
Viable 
Cells
% 
Viability
4 903 19 60 24.05
5 904 13 32 28.9
6 905 8 33 19.51
7 906 16 9 64
8 910 725 3015 19.38
9 911 28 65 30.11
10 912 545 5866 8.05
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Overall the results demonstrated that the lymphocyte viability was significantly 
decreased in samples that had been cryopreserved compared with those that 
had been stored at 4°C. 
3.1.2 ELISA study 
Figure 3.1 shows the development of colour in some of the wells of the 
microtitre plate after 10 minutes of adding the Stop solution.
 
Figure 3.1. An original photograph showing the ELISA microwell plate. 
The standards are shown in column 1 and 2.  
The absorbance readings for the standards in the ELISA was set at 450nm and 
the data are shown in table 3.4 for information. 
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Table 3.4.  The absorbance of the ELISA standards read at 450 nm. 
 
From the data a standard curve was produced and this is shown in figure 3.2 
 
 
Figure 3.2 The absorbance at 450 nm of standard concentrations of  
TNF-α. 
The TNF- α concentrations were determined using the standard curve and are 
given in Table 3.5. These concentrations were multiplied by 2 to account for the 
dilution factor from the ELISA protocol.  
 
Concentration of TNF-α 
pg/ml
Absorbance at 450 nm
500 2.62
250 1.58
125 0.92
62.5 0.49
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Table 3.5. The concentrations of TNF-α in patient samples 2-11. Data are 
the mean for 2 readings from each patient. 
 
3.1.3 Statistical analysis for cellular viability data. 
A two-tailed, paired samples, t-test was performed. This showed a significant 
difference in cellular viability between the refrigerated and cryopreserved 
samples when using Trypan Blue with the samples stored in the fridge having 
a. higher viability than the cryopreserved samples, (t(7)=5.029, 
p<.01).Consequently all future samples were refrigerated.  
3.1.4 Statistical Analysis for ELISA data 
A two-tailed Pearson’s correlation coefficient was performed. This shows no 
significant correlation between the concentrations of TNF-α and the sample 
age. (r=0.886, n=10, p<0.01). Although this p-value result suggests a positive 
correlation the experiment was affected by the single outlier of sample 11 and 
so these results were discounted. With the outlier excluded the significance 
disappears (r=0.650, n=9, p>0.05). A greater number of samples are required 
Patient Mean Absorbance [TNF-α] / 2 pg/ml [TNF-α ] Age of 
2 0.107 12.6 25.2 8
3 0.098 12.4 24.8 7
4 0.096 12.4 24.8 7
5 0.094 12.4 24.8 5
6 0.088 12.3 24.6 5
7 0.088 12.3 24.6 4
8 0.093 12.4 24.8 5
9 0.094 12.4 24.8 6
10 0.109 12.6 25.2 6
11 0.269 42 84 13
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to verify if this was a rogue result or an indication of increasing production of 
TNF-α connected to the age of the sample. 
There was also no correlation between age of sample and viability using trypan 
blue, (r=0.230, n=10, p=0.523). There was no correlation between the 
concentration of TNF-α and the percentage viability using trypan blue, (r=0.104, 
n=10, p=0.776). 
3.2 Presence of Tregs in high and low grade gliomas 
Data from the previous study indicated that cryopreservation of lymphocytes 
was not the optimum method of storage for these cells for studying both the cell 
surface proteins and the secretions of the preserved cells. The availability of 
buffy-coat samples collected by the Royal Preston Hospital was an attractive 
option to collect an adequate number of samples for this study. 
Jacobs, et al. (2012) reported an increase in the Treg population in the 
peripheral blood of malignant melanoma patients compared with patients with 
benign tumours with increased in the number of Tregs correlated with grade of 
tumour. This experiment was therefore performed to evaluate whether such a 
difference was evident in the peripheral blood of high grade (glioblastoma) 
patients and low grade (meningioma) patients. 
The results show that thawing at 4°C resulted in a greater number of viable 
cells than thawing at 37°C. The average percentage of viable cells for the 
samples thawed at 4°C was 69.69% and for samples thawed at 37°C was 
54.58% as shown in Tables 3.6 and 3.7. As a result, each sample was thawed 
at 4°C. 
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Table 3.6. The percentage of viable cells from slow thawing.  
 
   
Table 3.7 The percentage of viable cells from fast thawing. 
 
 
 
 
 
 
 
 
 
 
 
Sample no. Percentage of viable cells
1871 78.2
1891 53.72
1880 28.45
2231 78.9
2242 86.54
2251 73.21
2253 88.79
Average 69.69
Sample no. Percentage of viable cells
1889 10.1
1892 11.34
1877 18.57
1932 88.34
1937 79.02
2254 93.45
2261 81.23
Average 54.58
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3.2.1 Treg Quantification 
The WBC count and the volume of the sample were different for each sample. 
Samples with 1x106 cells/ml or more (>1x106 cells/ml) were used for the Treg 
detection method. The total WBC count for each sample is given in Table 3.8.  
Table 3.8.  The WBC and volume taken of the samples used in the study 
 
 
 
 
 
 
 
 
 
 
 
Sample no. WBC count (x106 cells/ ml)
Total volume of 
sample (ml)
Volume 
taken 
(µl)
GBM Patients (8)
1893 20.6 0.5 97
2215 15.3 0.5 130
2225 9.5 1.3 210
2238 0.1 1.5 1500
2251 2.5 0.7 400
2209 15.7 1 64
2263 87.4 0.1 11.44
1956 14.2 0.5 70
Meningioma Patients (4)
1906 11.1 1 90
1910 11.1 0.5 90
1959 19.3 1 103.6
1969 10.2 0.5 196
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3.2.2 Analysis of immunosuppressive Tregs using Flow cytometry 
Lymphocytes were gated using the forward and side scatter dot plot. The 
percentage amount of CD4+CD25+FoxP3+ Treg cells was measured using 
the CD25+FoxP3+ cell population transferred to the CD4+ gate, (see figure 
3.3). In this figure A and B are two gatings on samples from the same patient. 
The left hand boxes are a plot of forward scatter versus side scatter. The 
cloud in the lower right hand corner with high forward scatter and low side 
scatter are the lymphocyte population according to the manufacturer’s 
instructions. There is significant cellular debris in this plot. This gate is then 
used to analyse the CD4+ population which isolates T lymphocytes from the 
rest of the lymphocyte population. This is shown in the middle two boxes of 
figure 3.3. Finally this gating is transposed to the third box on the right hand 
side of figure 3.3 which is a plot of FoxP3 versus CD25. Cells in the upper 
right quadrant are therefore CD4+CD25+FoxP3+ cells which are the Treg 
population. Naive T cells (CD4+CD25-) were identified in the same way. 
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Figure 3.3. Flow cytometry of regulatory T cells. A and B are two gatings 
from the same patient. 
The mean, standard deviation and standard error of the mean of the percentage 
of CD4+CD25+FoxP3+ cells (Tregs) for both groups is shown in Table 3.9. 
These results were lower (1.71 ± 0.217%) in GBM patients compared with 
meningioma patients (2.19 ± 0.45%). The standard deviation was 0.619 in GBM 
and 0.9 in meningioma patients. The data show no significant difference 
between the two groups.  
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Table 3.9.  CD4+CD25+FoxP3+ cells (%) in GBM and meningioma buffy 
coat samples with Mean, Standard Deviation and Standard 
Error.  
 
3.2.3 Statistical analysis 
A Student’s t-test with unequal variance was performed on the mean T 
regs amount in both cohorts of patients with p= 0.418 which indicate no 
significant difference between the groups. 
 
 
 
 
 
 
 
Sample %Tregs in GBM % Tregs in Meningioma
1 1.82 3.21
2 1.98 2.18
3 0.34 2.34
4 1.47 1.02
5 2.21
6 2.25
7 1.67
8 1.96
Mean 1.71 2.19
Std. Dev 0.612 0.9
Std. error 0.217 0.45
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3.2.4 Analysis of naïve Treg cell population 
Naïve T cells are CD4+CD25- T cells produced by the bone marrow and have 
undergone differentiation in the thymus but have not yet encountered an 
antigen. This analysis was done to determine whether there were significant 
differences between the two cohorts in this population of cells that were later 
normalised following conversion of cells to the immunosuppressive Treg 
subtype. 
The results show that there was no significant difference (p>0.05) in the amount 
of naïve (CD4+CD25-) T cells in GBM (10.04%) and Meningioma (11.56%) as 
shown in table 3.10. 
Table 3.10. Data showing CD4+CD25- T cells (%) in GBM and Meningioma 
patient sample with calculated Mean, Standard Deviation and Standard 
Error. 
 
A Student’s t-test with unequal variance was performed on the mean naïve T 
cell amount in both cohorts of patients with p= 0.717 which indicate no 
significant difference between the groups. 
 
Sample %Tregs in GBM % Tregs in Meningioma
1 12.34 12.45
2 9.26 9.58
3 28.64 9.32
4 7.02 14.89
5 9.1
6 8.56
7 4.93
8 0.47
Mean 10.04 11.56
Std. Dev 8.3 2.63
Std. error 3.54 1.32
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3.3 Role of immunosuppressive cytokines 
Data from the previous study indicated that the number of regulatory T cells 
was not increased in patients with both malignant and non-malignant tumours 
of the CNS. This work aimed to establish whether there were any differences 
in circulating serum cytokine levels of these patients compared to non-
cancerous control patients and the possible site of production of these 
cytokines.  
These results show that there were significant differences (p<0.05) in serum 
analytes between pre and post-operative levels for three of the eight cytokines 
IL-6, IL- 8, IL-10 (p<0.05) (see figure 3.4). Moreover, there was also a significant 
difference (p<0.05) between pre and post-operative levels for three of the eight 
cytokines IL-6, IL-8 and IL-10 measured when compared to the control values. 
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Figure 3.4. The concentrations (pg/ml) of IL-6, IL-8 and IL-10 in the sera of 
pre and post-operative patients. Data are mean +/- 2SD, p<0.05, n = 36 
paired samples from GBM patients undergoing surgery for removal of 
tumour. 
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The serum analytes that do not show a statistical difference (p<0.05) between 
non-cancerous control serum and GBM are G-CSF, HGF, Leptin and VEGF, 
(See table 3.12). 
The serum analytes show a statistical difference (p<0.05) between non-
cancerous control serum and GBM are angiopoietin, follistatin, IL-8, PDGF-BB 
and PECAM-1. (See figure 3.5). 
Table 3.11 Mean values and standard deviations of angiogenesis factor 
concentrations for non-cancerous (n=27) and high grade (n=50) glioma 
sera samples with no significant difference. 
 
 
 
 
 
 
 
Cytokine Mean (pg/ml) standard deviation n paired differences significance p<0.05
G-CSF non-cancerous 3.1 0.29 27 no
high grade 3.1 0.61 50 0 no
HGF non-cancerous 738.9 79.6 27 no
high grade 724.7 142.3 50 14.2 no
Leptin non-cancerous 9102.6 1533 27 no
high grade 10312.3 1685.3 50 1209.7 no
VEGF non-cancerous 85.2 5.5 27 no
high grade 75.4 20.9 50 9.8 no
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Figure 3.5 Bar charts a) to e) show the analyte levels (pg/ml) between 
glioma and non-cancerous serum. Data are mean +/- 2sd, 
n=50 glioma, 27 non-cancerous control, p<0.05 for glioma 
compared to non-cancerous control. The significant 
differences * = p<0.05, *** = p<0.001, between non-cancerous 
control and high grade glioma sera are shown above the 
histograms. 
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3.4 Immunohistochemistry of follistatin 
The aim of this study was to determine the likely source of production, either 
from the tumour cells or elsewhere, of the increased biomarkers follistatin, to 
determine if there were any differences in the pattern of expression between 
low and high grade glioma tissue specimens. The study analysed 12 high 
grade, 6 low grade and 6 non-cancerous specimens. The stained specimens 
were graded as 1, 2 or 3 according to the intensity of staining in the nucleus, 
cytoplasm or interstices using the scoring system outlined in chapter 2.  
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3.4.1 Results of follistatin staining  
High grade, low grade and non-cancerous glioma – Follistatin staining 
 
 
 h.)  
Figure 3.6 Original photographs showing follistatin staining in both 
high grade glioma, (a),(b),(d),(e) and non-cancerous brain 
sections, (c) and (f) mag x40. Typical staining of 12 high 
grade and 6 non-cancerous sections from different patients. 
(g) shows choroid plexus tissue staining. (h) shows 
follistatin staining in a low grade glioma mag x100. Typical 
staining of 6 sections from different patients. Black scale bar 
represents 20 microns (a-g) and 100 microns (h) 
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Immunohistochemical analysis in this study demonstrated an increased rate of 
follistatin immunostaining in low grade gliomas (positive in 66% of specimens 
tested) than high grade gliomas (positive in 33% of specimens tested). 
Furthermore, the low grade gliomas exhibited +++ immunostaining in all that 
were positive whereas in high grade gliomas the intensity of staining in positive 
specimens was only +. Figure 3.6 (h) is a typical example of +++ 
immunostaining in a low grade glioma section. There were also differences in 
the pattern of staining between low and high grade gliomas with the low grade 
gliomas displaying a predominately interstitial stain with axonal staining. The 
high grade gliomas displayed a wider variety of staining patterns with both 
interstitial and cytoplasmic staining. In both grades of glioma nuclear staining 
was absent. All 6/6 non-cancerous specimens were uniformly negative in 
nuclear, interstitial and cytoplasmic staining.  
3.5 Immunohistochemistry of leptin 
Leptin was found to be neither significantly increased or decreased in the serum 
of glioma patients. The aim of this study was to determine the likely source of 
production, of the potential biomarker leptin and to determine if there were any 
differences in the pattern of expression between primary low and high grade 
glioma tissue specimens. Immunohistochemical staining of Leptin in 13 high 
grade glioma, 4 low grade glioma and 4 non-cancerous brain tissue samples 
was performed according to the protocol described in chapter 2. Testis and 
ovarian tissue were stained as a negative control. The stained specimens were 
graded as outlined in chapter 2 according to the intensity of staining in the 
nucleus, cytoplasm or interstitial space (table 3.12). 
138 
 
3.6 Results of leptin staining 
a)      
b)    
c)      
   c) 
Figure 3.7 Original photographs showing leptin staining in, a) high 
grade b) low grade glioma and c) non-cancerous brain 
sections, mag x40 (a and b) x10 (c) Typical staining of 13 high 
grade, 4 low grade and 4 non-cancerous sections. Black 
scale bar represents 20 microns (a and b) and 200 microns 
(c). 
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Table 3.12 The grading of leptin expression in high grade glioma, low 
grade glioma, non-cancerous brain, testicular and ovarian 
tissue from immuno-histochemical staining.  
 
 
 
The results of the study have clearly shown that the expression of leptin was 
observed in the cytoplasm and in the interstitial spaces of tumour cells of both 
grades (figures 3.7a and b) with little staining observed in normal brain tissue 
(figure 3.7c). 
High grade glioma specimens displayed predominately, (12/13), cytoplasmic 
and interstitial staining with no nuclear localisation. In addition, 1/13 specimens 
displayed weak (+) nuclear localisation. Interstitial staining was graded as (+) 
for 8/12 of these specimens, (++) for 4 specimens and (+++) for 1 specimen. 
BTNW No. Malignancy Type Nucleus Cytoplasm Interstitial Space
1044 Low Grade - + +
1028 Low Grade - + + +
934 Low Grade - + + + +
1005 Low Grade + + + +
NB 288/11 High Grade - ++ +
NB 361/11 High Grade - + + + + +
NB 431/11 High Grade - + +
NB 250/11 High Grade - + + + + +
NB 302/11 High Grade - + +
NB 293/11 High Grade - + + + +
NB 767/11 High Grade - + +
NB 505/11 High Grade - + + + +
NB 570/11 High Grade - + +
NB 568/11 High Grade + + + + + + +
NB 24/12 High Grade - + +
NB 815/11 High Grade - + +
NB 576/11 High Grade - + +
Testis Normal Tissue - - +
Ovary Normal Tissue - - -
Brain 1 Normal Tissue - - +
Brain 2 Normal Tissue - - +
Brain 3 Normal Tissue - - +
Brain 4 Normal Tissue - + +
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Cytoplasmic staining was (+) for 6 specimens, (++) for 4 specimens and (+++) 
for 3 specimens (table 3.12).  
Low grade glioma specimens displayed cytoplasmic and interstitial staining and 
nuclear localisation of less intensity than the high grade gliomas. There was no 
nuclear localisation in 3/4 specimens and (+) localisation in 1/4. All of the 
specimens (4/4) displayed (+) interstitial staining. 3/4 specimens displayed (++) 
cytoplasmic staining with 1/4 displaying (+) cytoplasmic staining. The main site 
of leptin production in low grade gliomas was the cytoplasm. 
The results also show that non-cancerous brain specimens displayed very little 
localisation in the nucleus, interstitial space and cytoplasm. All, (4/4), 
specimens were immuno-negative in the nucleus whilst they were all, (4/4), (+) 
in the interstitial space. In the cytoplasm 1/4 specimens were (+) and 3/4 were 
immuno-negative. Non-cancerous ovarian and testicular tissue was used as a 
negative control in this experiment. 
3.7 Immunohistochemistry of Prolactin  
The serum levels of prolactin in both low and high grade gliomas were 
significantly raised in comparison to non-cancerous controls. The aim of this 
study was to determine if this increase was matched by increased expression 
in primary tissue. This study analysed 12 high grade, 6 low grade and 6 non-
cancerous specimens. The stained specimens were graded as 1, 2 or 3 
according to the intensity of staining in the nucleus, cytoplasm or interstices 
using the scoring system outlined in chapter 2. 
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3.8  Results of prolactin staining 
a)   b) 
  
 
 c)   d)  
Figure 3.8 Original photographs showing prolactin staining in, a) low 
grade glioma mag x10, b) high grade glioma mag x40, c) non-
cancerous brain mag x10 and d) normal breast tissue mag 
x40. Typical staining of 12 high grade, 6 low grade and 6 non-
cancerous sections. Arrows point to areas of staining. Black 
scale bar represents 200 microns (a and c) and 20 microns 
(b and d). 
 
 
The expression of prolactin was observed in 1/6 (16.7%) low grade glioma 
samples (Figure 3.8a) and in 3/12 (25%) high grade glioma samples (figure 
3.8b). In both grades all staining was weak with a staining intensity score of 1. 
The staining was cytoplasmic only with no interstitial staining or nuclear 
localisation. Non-cancerous control specimens (figure 3.8c) were all uniformly 
negative in nuclear, interstitial and cytoplasmic staining. Normal breast tissue 
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(figure 3.8d) was stained alongside the tumour and non-cancerous sections and 
was strongly positive with a staining intensity score of 3 for cytoplasmic and 
interstitial staining and nuclear localisation. 
3.9  Immunohistochemistry of PDGF 
 
The study analysed 18 high grade and 6 non-cancerous specimens. The 
sections were stained with the following primary antibodies: PDGFRα, PDGF-
AA, PDGF-BB and PDGFRβ.  
The stained specimens were graded as 1, 2 or 3 according to the intensity of 
staining in the nucleus, cytoplasm or interstices using the scoring system 
outlined in chapter 2.  
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3.10 Results of PDGF staining 
a)      b)  
 
     c)         d)      
 
     e)        f)  
 
    g)        h)  
 
Figure 3.9 Original photographs showing the expression profile of a 
single high grade patient for PDGF AA (figure 3.9a), PDGFRα 
(figure 3.9b), PDGF BB (figure 3.9c) and PDGFRβ (figure 3.9d) 
and a non-cancerous control for PDGF AA (figure 3.9e), 
PDGFRα (figure 3.9f), PDGF BB (figure 3.9g) and PDGFRβ 
(figure 3.9h). Black scale bar represents 20 microns. 
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The results show that 93.75% of GBM patients displayed increased PDGFRα 
expression compared to the non-cancerous controls. In addition, 75% of GBM 
patients displayed increased PDGF-BB expression and 43.75% of GBM patients 
displayed increased PDGF-AA expression. However, 56.25% of GBM patients 
displayed decreased expression of PDGFRβ. The staining was mostly 
cytoplasmic although 2 patients displayed some interstitial staining (see figure 
3.9c). Staining intensity was strong with a score of 3. A total of 6 primary GBM 
patients underwent both immunohistochemistry ligand staining and serum 
analysis. Table 3.13 shows the staining score for patients and corresponding 
serum concentration. 
 
 
 
     3.11 Correlation between PDGF protein expression and 
serum composition in primary glioblastoma. 
 
Table 3.13 showing staining score and corresponding serum 
concentration 
 
 
 
As the results for both serum levels and tissue expression of the PDGF family 
for 6 patients were obtained it was possible to determine whether there was 
any significant correlation between the groups. The results show that there was 
a significant correlation between PDGF-BB ligand expression and PDGF-AA 
PDGF-AA PDGF-BB PDGF-AA PDGF-BB
1122 28590 342.3 2 2 2 1
511 32180 395.1 2 3 3 3
1154 30440 832.7 3 3 3 2
375 27360 968.2 2 2 3 3
1156 28370 779.9 2 3 2 2
1
BTNW no.
Serum concentration (pg/ml) Staining score
PDGFRα 
PDGFRβ
1121 21610 570.1 3 1 3
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serum concentration (r=0.89, p<0.05). There was also some correlation 
between PDGFRα and PDGF-AA ligand expression (r=0.5, p<0.05). Please 
note the discrepancy in serum concentration results with PDGF-BB displayed 
in figure 3.5. This results from taking measurements using different 
methodologies, (i.e. Luminex and ELISA). The results are dependent upon the 
calibration of the instruments and the specificities of the reagents and reference 
standards used. 
3.12  Evaluation of serum and CSF biomarkers for glioma 
This study aimed to evaluate the clinical usefulness of an array of potential 
biomarkers in serum and CSF by comparing the levels of the marker between 
non-cancerous, high grade glioma and low grade glioma patients. 
3.13 Study Protocols 
This work comprised of four protocols and they included the following; 
1. Comparison of 8 analytes associated with inflammation in 6 patients before and 
during anaesthetic administration. 
2. Comparison of 34 analytes in 44 low grade, 115 high grade and 33 control 
serum samples. Survival data were obtained for 53 of the high grade patients 
and a comparison with cytokine levels for each measured significant analyte 
was made. 
3. Comparison of 34 analytes in 8 high grade and 8 control CSF samples 
4. Comparison of 34 analytes in 59 high grade pre-debulking serum samples, 50 
high grade post debulking samples, 14 control pre-operative samples and 19 
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control post-operative samples. The control operations were for invasive 
surgery for non-cancerous conditions using the same anaesthetic protocol. 
3.14 Study 1. Anaesthetic effect 
Samples were taken both before and during anaesthetic administration. Initially 
a study was performed to detect whether the anaesthetic drugs had an effect 
on circulating cytokine levels. This involved taking blood samples from 6 
patients before anaesthetic was given as well as during the operation from 
those same patients whilst under anaesthetic. The 8 analytes chosen for this 
study reflected the most reactive cytokines traditionally associated with the 
inflammatory response. These were IL-2, IL-4, IL-6, IL-8, IL-10, GM-CSF, INF-
γ and TNF-α. None of the 6 paired human serum cytokine concentrations 
demonstrated a significant difference (p>0.05) between pre-anaesthetic levels 
and post-anaesthetic levels as shown in Table 3.14. 
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Table 3.14.  The mean cytokine concentrations in pg/ml between paired 
samples taken before and after general anaesthetic. 
 
 
3.15 Study 2.  Comparison of 44 low grade, 115 high grade and 33 control 
serum samples. 
Study 1 established that anaesthetic given to glioma patients did not affect the 
production of the most reactive cytokines. This enabled the collection of pre 
and post-operative samples without the need to account for any anaesthetic 
effect. Therefore the aim of study 2 was to compare blood serum levels of 34 
analytes that have been implicated in other cancers and in angiogenesis to 
determine if any were suitable as a potential biomarker to aid diagnosis of high 
and low grade glioma. Tables 3.15 and 3.16 show the concentrations of the 
Mean pg/ml N
Paired 
differences 
pg/ml Significance (p<0.05)
IL-2 Preanaesthetic 2307.91 6
IL-2 Postanaesthetic 2301.41 6 6.5 No
IL-4 Preanaesthetic 3562.32 6
IL-4 Postanaesthetic 3559.21 6 3.11 No
IL-6 Preanaesthetic 3186.57 6
IL-6 Postanaesthetic 3183.67 6 2.9 No
IL-8 Preanaesthetic 1273.02 6
IL-8 Postanaesthetic 1271.81 6 1.21 No
IL-10 Preanaesthetic 4838.82 6
IL-10 Postanaesthetic 4836.32 6 2.5 No
GM-CSF Preanaesthetic 2523.87 6
GM-CSF Postanaesthetic 2520.41 6 3.46 No
IFN-γ Preanaesthetic 1801.05 6
IFN-γ Postanaesthetic 1800.99 6 0.06 No
TNF-α Preanaesthetic 3156.07 6
TNF-α Postanaesthetic 3155.83 6 0.24 No
Pair 6
Pair 7
Pair 8
Cytokine
Pair 1
Pair 2
Pair 3
Pair 4
Pair 5
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different biomarkers in the analysis. The results clearly show no significant 
difference between any of the three groups (low grade, high grade and non-
cancerous). Figure 3.10 shows that analytes had some significant difference 
between the three groups. 
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Table 3.15.  Mean values for non-cancerous (n=33) and low grade (n=44) 
glioma sera samples with no significant difference. These 
results were generated with those in figure 3.10 and should 
be read in conjunction with those. 
 
Cytokine Median pg/ml Mean -/+ sd pg/ml N
Paired differences of 
means pg/ml
Significance (p<0.05)
sEGFR Non-cancerous 17351 17582 -/+ 906 33
Low grade glioma 18977 18841 -/+ 904 44 1259 No
HGF Non-cancerous 3157 3175 -/+ 106 33
Low grade glioma 2540 2622 -/+ 94 44 553 No
Osteopontin Non-cancerous 30345 34092 -/+ 2932 33
Low grade glioma 30541 34582 -/+ 2849 44 490 No
SCF Non-cancerous 452 458 -/+ 12 33
Low grade glioma 443 471 -/+ 18 44 13 No
TIE-2 Non-cancerous 12092 12457 -/+ 494 33
Low grade glioma 12269 12673 -/+ 467 44 216 No
sVEGFR-2 Non-cancerous 4962 5107 -/+ 268 33
Low grade glioma 5309 5574 -/+ 248 44 467 No
sCD40L Non-cancerous 1157 1193 -/+ 63 33
Low grade glioma 1146 1225 -/+ 60 44 32 No
Endoglin Non-cancerous 1130 1267 -/+ 76 33
Low grade glioma 1131 1231 -/+ 72 44 36 No
sFASL Non-cancerous 298 299 -/+ 9 33
Low grade glioma 309 318 -/+ 7 44 19 No
HB-EGF Non-cancerous 56 58 -/+ 2 33
Low grade glioma 61 62 -/+ 2 44 4 No
IGFBP-1 Non-cancerous 7174 14104 -/+ 2535 33
Low grade glioma 9241 14127 -/+ 1885 44 23 No
IL-6 Non-cancerous 50 65 -/+ 10 33
Low grade glioma 45 54 -/+ 9 44 11 No
IL-8 Non-cancerous 18 20 -/+ 2 33
Low grade glioma 16 16 -/+ 1 44 4 No
IL-18 Non-cancerous 214 235 -/+ 16 33
Low grade glioma 205 251 -/+ 30 44 16 No
PAI-1 Non-cancerous 189738 228010 -/+ 22587 33
Low grade glioma 199743 262072 -/+ 28253 44 34062 No
PLGF Non-cancerous 83 85 -/+ 3 33
Low grade glioma 86 85 -/+ 3 44 0 No
TGF-α Non-cancerous 92 100 -/+ 6 33
Low grade glioma 98 99 -/+ 4 44 1 No
TNF-α Non-cancerous 32 31 -/+ 1 33
Low grade glioma 32 32 -/+ 1 44 1 No
VEGF-A Non-cancerous 709 740 -/+ 61 33
Low grade glioma 719 722 -/+ 42 44 18 No
VEGF-C Non-cancerous 1926 1914 -/+ 98 33
Low grade glioma 2032 2136 -/+ 114 44 222 No
VEGF-D Non-cancerous 887 887 -/+ 15 33
Low grade glioma 903 881 -/+ 17 44 6 No
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Table 3.16.  Mean values for non-cancerous (n=33) and high grade 
(n=115) glioma sera samples with no significant difference. 
These results were generated with those in figures 3.10 and 
should be read in conjunction with those. 
 
 
Median 
pg/ml
Mean -/+ sd 
pg/ml
N
Paired 
differences 
pg/ml
Significance (p<0.05)
sEGFR Non-cancerous 17351 17582 -/+ 906 33
High grade glioma 18145 18047 -/+ 453 115 465 No
HGF Non-cancerous 3157 3175 -/+ 106 33
High grade glioma 2708 2712 -/+ 65 115 463 No
Osteopontin Non-cancerous 30345 34092 -/+ 2932 33
High grade glioma 31343 35907 -/+ 1948 115 1815 No
SCF Non-cancerous 452 458 -/+ 12 33
High grade glioma 454 435 -/+ 10 115 23 No
TIE-2 Non-cancerous 12092 12457 -/+ 494 33
High grade glioma 11550 11367 -/+ 273 115 1090 No
sVEGFR-2 Non-cancerous 4962 5107 -/+ 268 33
High grade glioma 5234 5255 -/+ 139 115 148 No
sCD40L Non-cancerous 1157 1193 -/+ 63 33
High grade glioma 1108 1178 -/+ 40 115 15 No
Endoglin Non-cancerous 1130 1267 -/+ 76 33
High grade glioma 1071 1154 -/+ 41 115 113 No
sFASL Non-cancerous 298 299 -/+ 9 33
High grade glioma 308 308 -/+ 3 115 9 No
HB-EGF Non-cancerous 56 58 -/+ 2 33
High grade glioma 62 68 -/+ 2 115 10 No
IGFBP-1 Non-cancerous 7174 14104 -/+ 2535 33
High grade glioma 10180 17300 -/+ 1521 115 3196 No
IL-6 Non-cancerous 50 65 -/+ 10 33
High grade glioma 43 46 -/+2 115 19 No
IL-8 Non-cancerous 18 20 -/+ 2 33
High grade glioma 15 19 -/+ 3 115 1 No
IL-18 Non-cancerous 214 235 -/+ 16 33
High grade glioma 175 207 -/+ 12 115 28 No
PAI-1 Non-cancerous 189738 228010 -/+ 22587 33
High grade glioma 212391 236085 -/+ 10559 115 8075 No
PLGF Non-cancerous 83 85 -/+ 3 33
High grade glioma 80 79 -/+ 1 115 6 No
TGF-α Non-cancerous 92 100 -/+ 6 33
High grade glioma 98 99 -/+ 2 115 1 No
TNF-α Non-cancerous 32 31 -/+ 1 33
High grade glioma 30 30 -/+ 1 115 1 No
VEGF-A Non-cancerous 709 740 -/+ 61 33
High grade glioma 737 769 -/+ 26 115 29 No
VEGF-C Non-cancerous 1926 1914 -/+ 98 33
High grade glioma 2022 2093 -/+ 57 115 179 No
VEGF-D Non-cancerous 887 887 -/+ 15 33
High grade glioma 856 854 -/+ 7 115 33 No
Cytokine
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          Figure 3.10 Scatterplots and table displaying the concentrations of 10 analytes including; a) FGF-basic, b) Follistatin, c) 
G-CSF, d) sHER2-neu, e) PDGF ABBB, f) sIL-6Ralpha, g) PECAM-1, h) Prolactin, i) sVEGFR-1, j) uPA in sera taken from patients 
with low and high grades of glioma compared to a non-cancerous group. The significant differences * = p<0.05, ** = p<0.01, *** 
= p<0.001, **** = p<0.0001 between non-cancerous, low grade and high grade glioma sera are shown above the horizontal bars. 
The means and standard deviations are shown in grey for comparison. n= 33 for non-cancerous, 44 for low grade and 115 for 
high grade samples. These results are also shown in table 3.17. 
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 Table 3.17 displaying the results from figure 3.10 in numerical form. 
 
The data presented in figure 3.10 and table 3.17 show a variety of differences 
in serum levels of the potential biomarkers. 7/10 of these biomarkers including 
FGF-basic, Follistatin, G-CSF, PDGF ABBB, sIL-6Rα, Prolactin and sVEGFR-
1, showed increasing levels of the analyte in low and high grade glioma sera 
compared with the non-cancerous controls. In contrast 3/10, which included 
sHER2-neu, PECAM-1 and uPA showed decreasing levels in comparison. 
Several of the measured analytes including Prolactin, sVEGFR-1, FGF-basic, 
Follistatin, G-CSF, SHER2-neu, sIL-6Rα and uPA show potentials as 
diagnostic biomarkers. As such they seem to be promising candidates for 
diagnostic tools in the detection of glioma. Interestingly sIL-6Rα and uPA were 
able to distinguish between low and high grade gliomas, however, all of the 
potential biomarkers must go through the confirmation, assay development and 
validation stages of biomarker approval. Cancer Research UK have produced 
an indicative roadmap for a new biomarker validation that incorporates the 
above stages (Cancer Research UK, 2017). 
 
Mean pg/ml sd n Mean pg/ml sd n Mean pg/ml sd n
FGF-basic 184.6 4.9 33 239 12.5 44 216.6 4.5 115
Follistatin 1548.4 78.4 33 1954 93.7 44 2009.7 71.3 115
G-CSF 379.4 9.4 33 413.1 13.2 44 435.4 16.2 115
sHer2-neu 4845.3 252 33 4079.5 227.2 44 3615.8 13.4 115
PDGF-ABBB 7315.1 603.9 33 8572.4 391.9 44 8536.8 355.5 115
sIL-6R alpha 10352.8 669.4 33 9027.9 507.8 44 12242.3 455 115
PECAM-1 5382.4 236.7 33 4918 215 44 4907.3 147.4 115
Prolactin 8101.9 802.9 33 28875.1 3667.8 44 32603.8 3541.9 115
sVEGFR-1 736.6 27.2 33 1017.6 65.5 44 911.2 28.7 115
uPA 278.4 18.1 33 275.8 11.5 44 236.9 7.2 115
Cytokine
Non-cancerous Low grade High grade
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Statistical power analysis is a measure of the probability of rejecting a null 
hypothesis when the alternative hypothesis is true. In terms of this study it is a 
measure of the ability of each biomarker to predict the presence of a brain 
tumour. The mean and standard deviation (SD) of the non-cancerous, high-
grade and low-grade cohorts was calculated for each biomarker. An individual 
patient was considered positive if their result was above or below the mean of 
the non-cancerous cohort plus or minus 2SD depending whether the biomarker 
was raised or lowered in the glioma cohort compared to the non-cancerous 
control. Power analysis of the data in this study indicates that prolactin (100%), 
sVEGFr-1 (99.99%), FGF (99.8%), follistatin (99.6%), G-CSF (99.6%) and 
sHer2-neu (99%) are the strongest performing potential biomarkers. The 
specificity and sensitivity levels are summarised in Table 3.18. This study had 
sufficient sample sizes to demonstrate 80% power in 5 potential biomarkers 
with sHER2-neu being just outside of this sample size range. Moreover, 
sHER2-neu levels showed a decreasing gradation of levels between non-
cancerous, low grade and high grade sera. The specificity for distinguishing 
between low and high grade glioma was 51% for this analyte. 
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Table 3.18 The sensitivity and specificity of potential biomarkers in 
measuring serum levels of several analytes to distinguish 
sera from low grade and high grade glioma patients from 
sera from non-cancerous patients. All data are expressed as 
a percentage 
 
These data presented in table 3.18 were obtained by producing a reference 
range from the non-cancerous control data using a 95% confidence interval 
calculated by using the mean plus and minus 2 standard deviations. Individuals 
with levels outside of these ranges were considered abnormal and were 
deemed positive for the disease diagnosis depending whether the analyte is 
raised or lowered in the diseased cohort. The sensitivity of the biomarker is a 
measure of the ability of the biomarker to correctly measure the proportion of 
positives identified as such. This is also known as the true positive rate. The 
specificity of the biomarker measures the proportion of negatives identified as 
such also known as the true negative rate. 
Figure 3.11 shows the survival of high grade glioma patients from first 
diagnosis. The data showed that almost 80% of patients with high grade glioma 
  Analytes Power
Sample 
size for 
80% 
power
Sen. Spec. Sen. Spec.
Prolactin 70% 100% 83% 100% 100% 2
sVEGFr-1 59% 67% 69% 67% 99.99% 28
FGF 73% 82% 72% 82% 99.80% 28
Follistatin 64% 70% 70% 70% 99.60% 34
G-CSF 77% 67% 65% 67% 99.60% 32
sHER2-Neu 59% 64% 76% 64% 99.00% 49
LGG HGG
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died within 20 months of first diagnosis. By 5 years after diagnosis all patients 
had died. 
Survival data of high grade glioma patients from first diagnosis
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Figure 3.11. Kaplan-Meier plot of survival for 53 high grade glioma 
samples 
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Table 3.19 shows that there was no correlation with the levels of any analyte 
with either survival or gender. 
Table 3.19 The correlation between the level of the potential biomarker 
(pg/ml) and survival in months (r) and the probability (p) of a 
correlation in gender (male or female). Correlation coefficient 
r > +/- 0.5 and p <0.05 to be considered correlated. See 
Appendix A for data set. 
 
 
 
Gender p 
value
Survival r 
value
uPA None -0.127 None 0.05
PDGF- 
ABBB
None 0.191 None 0.41
sIL-6R alpha None -0.036 None 0.33
PECAM-1 None 0.005 None 0.61
G-CSF None -0.048 None 0.64
sHER2-Neu None 0.083 None 0.24
FGF - basic None 0.035 None 0.36
Follistatin None 0.025 None 0.39
0.08
sVEGFr-1 None -0.031 None 0.23
Analytes
Correlation 
with 
survival 
Correlation 
with gender
(male or
female) 
Prolactin None 0.279 None
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3.16 Study 3. Measurements of potential biomarkers in 8 high grade and 8 
control CSF samples 
The aim of the third part of the study was to determine whether Cerebro-Spinal 
Fluid (CSF) could also be used either in place of or alongside blood serum as 
a source of potential diagnostic biomarkers for high grade glioma. A further aim 
was to determine if the same analytes that were significantly different in blood 
serum were also significantly different in CSF. The data presented in figure 3.12 
and table 3.20 showed that there was some correlation between those 
biomarkers identified as being significantly, (p<0.05) dysregulated in sera and 
those biomarkers identified as significantly different in CSF. In addition, other 
significantly, (p<0.05) dysregulated biomarkers were detected in the CSF that 
were not identified as dysregulated in the sera. These were sEGRF and SCF. 
(figure 3.12). 
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Table 3.20 Mean values for non-cancerous (n=8) and high grade (n=8) 
glioma CSF samples with no significant difference. These results were 
generated with those in figures 3.12 and should be read in conjunction 
with those. 
 
Cytokine Mean (pg/ml) standard deviation n paired differences significance p<0.05
non-cancerous 121.6 52 8 63.1
high grade 184.7 27.9 8 no
non-cancerous 507.1 203.3 8 281.3
high grade 788.4 176.6 8 no
non-cancerous 1313.7 511 8 271.9
high grade 1041.8 308.3 8 no
non-cancerous 555.6 308.3 8 44.7
high grade 510.9 359.1 8 no
non-cancerous 1906.3 723.6 8 -794.1
high grade 2700.4 246.5 8 no
non-cancerous 170.3 86.7 8 -113
high grade 283.3 69.8 8 no
non-cancerous 44125.3 23420.5 8 30569.9
high grade 13555.4 21761.2 8 no
non-cancerous 3708.4 2035 8 -2784.1
high grade 6492.5 1665 8 no
non-cancerous 2504 1515.7 8 -1493.6
high grade 3997.6 548.6 8 no
non-cancerous 387.4 117.3 8 161.1
high grade 226.3 79.1 8 no
non-cancerous 488.2 127 8 51.9
high grade 436.3 217.3 8 no
non-cancerous 257.6 176.3 8 95.8
high grade 161.8 70.2 8 no
non-cancerous 36.3 7.6 8 5.1
high grade 31.2 5.1 8 no
non-cancerous 9090.1 5829.5 8 4799.5
high grade 4290.6 1748.7 8 no
non-cancerous 351.7 320.4 8 308.2
high grade 43.5 36.7 8 no
non-cancerous 1757.6 2386.7 8 1483.6
high grade 274 472.1 8 no
non-cancerous 52.4 18.9 8 -16.4
high grade 68.8 46.6 8 no
non-cancerous 24225 16028.5 8 -9218
high grade 33443 11596.1 8 no
non-cancerous 268.4 53.2 8 17.7
high grade 250.7 92.2 8 no
non-cancerous 74.1 18.1 8 19.9
high grade 54.2 10.8 8 no
non-cancerous 26 6.4 8 9.5
high grade 16.5 3.6 8 no
non-cancerous 504.4 111.1 8 95.6 no
high grade 408.8 129.7 8 no
non-cancerous 747.3 431.8 8 437.2
high grade 310.1 98.4 8 no
non-cancerous 987 236.6 8 299
high grade 688 130.6 8 no
non-cancerous 640.7 109.9 8 121.9
high grade 518.8 72.1 8 no
VEGF-D
Prolactin
uPA
PAI-1
PLGF
TGF-α
TNF-α
VEGF-A
VEGF-C
sFASL
HB-EGF
IGFBP-1
IL-6
IL-8
IL-18
PDGF- ABBB
Osteopontin
TIE-2
sVEGFR-2
sCD40L
Endoglin
Leptin
FGF-basic
sHer2- neu
HGF
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Figure 3.12 Scatterplots displaying the concentrations of 8 analytes namely; a) sEGRF, b) Follistatin, c) G-CSF, d) sIL-6Ralpha, 
e) PECAM-1, f) SCF, g) sVEGFR-1 in CSF in non-cancerous control and high grade glioma samples. The significant differences 
* = p<0.05 and *** = p<0.001, between non-cancerous, and high grade glioma CSF samples are shown above the horizontal bars. 
The means and standard deviations are shown in grey for comparison. n= 8 for non-cancerous and high grade samples. These 
results are also shown in table 3.21. 
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Table 3.21 displaying the results from figure 3.12 in numerical form. 
 
3.17 Study 4. Measurements of biomarkers in 59 high grade pre-debulking 
serum samples, 50 high grade post debulking samples, 14 control pre-op 
samples and 19 control post op samples for comparison. 
So far, studies 1-3 in this investigation have shown no significant change in 
inflammatory cytokines during the administration of general anaesthetic before 
surgery. However, the data have established significant differences in several 
analytes between non-cancerous control patients, low grade glioma and high 
grade glioma patients in serum and CSF. There was also some correlation in 
sera and CSF of a number of potential biomarkers that were dysregulated in 
high grade glioma, suggesting that the production of these potential biomarkers 
were from the same source.  
Study 4 aimed to test whether there was a significant change in the levels of 
these analytes following de-bulking of tumour surgery which would allow for the 
monitoring of surgical treatment through measuring analyte levels post 
operatively, as well as providing evidence for the source of production of the 
circulating biomarker. Of the analytes investigated, Follistatin, G-CSF and 
Mean pg/ml sd n Mean pg/ml sd n
sEGFR 2740.6 500.7 8 8500.5 2325.9 8
Follistatin 657.5 124.8 8 928.6 64.8 8
G-CSF 289.8 32.7 8 434.7 56.7 8
sIL-6R alpha 802.7 205.2 8 2191.6 543.7 8
PECAM-1 1326 99.6 8 1878.7 217.4 8
SCF 157 32 8 337.1 42.6 8
sVEGFR-1 385 44.8 8 632.2 97.2 8
cytokine
Non-cancerous High grade
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Prolactin showed a significant (p<0.05) reduction in detectable levels in the sera 
of glioma patients after surgery compared to the control. In contrast no 
significant difference was detected in the sera of non-cancerous patients post-
operatively compared to pre-operatively (figure 3.13). 
       
a
Follistatin
N
on
-c
an
ce
ro
us
 p
re
N
on
-c
an
ce
ro
us
 p
os
t
H
ig
h 
gr
ad
e 
pr
e
H
ig
h 
gr
ad
e 
po
st
0
2000
4000
6000
8000
*
p
g
/m
l
b
G-CSF
N
on
-c
an
ce
ro
us
 p
re
N
on
-c
an
ce
ro
us
 p
os
t
H
ig
h 
gr
ad
e 
pr
e
H
ig
h 
gr
ad
e 
po
st
0
200
400
600
800
1000
**
p
g
/m
l
c
Prolactin
N
on
-c
an
ce
ro
us
 p
re
N
on
-c
an
ce
ro
us
 p
os
t
H
ig
h 
gr
ad
e 
pr
e
H
ig
h 
gr
ad
e 
po
st
0
50000
100000
150000
***
p
g
/m
l
 
Figure 3.13 Scatterplots displaying the concentrations of 3 analytes 
namely; a) Follistatin, b) G-CSF and c) Prolactin. The significant 
differences * = p<0.05, ** = p<0.01 and *** = p<0.001, between non-
cancerous, and high grade glioma serum samples are shown above the 
horizontal bars. The means and standard deviations are shown in grey for 
comparison. Each solid, triangle and square represents one sample and 
n=  59 high grade pre-debulking serum samples, 50 high grade post 
debulking samples, 14 control pre-operative samples and 19 control post-
operative samples. The results are also shown in table 3.22. 
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Table 3.22 displaying the results from figure 3.13 in numerical form. 
 
In all 3 analytes, a high pre-operative level in the glioma patient samples 
reduced to levels that are almost comparative to non-cancerous sera in the 
post-operative sample. The non-cancerous sera did not show any significant 
difference between pre and post-operative levels. 
 
 
 
 
 
 
 
 
 
 
 
Mean pg/ml sd Mean pg/ml sd Mean pg/ml sd Mean pg/ml sd
Follistatin 1501.2 95.1 1583.2 118.4 2204.4 115.7 1881.5 94.4
G-CSF 392.9 17.3 417.3 49.2 497 27.5 427 14.2
Prolactin 6966.4 1312.3 8938.7 991.2 36956.4 5970.9 12903 1843.4
cytokine
Non-cancerous
Pre-op Post-op
High-grade
Pre-op Post-op
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General discussion 
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4.1 Introduction  
The aims of this thesis were twofold. The first was to investigate the role of 
lymphocyte subsets in the generation of an immunosuppressive 
microenvironment in glioma patients in order to identify a possible therapeutic 
target. After an investigation into the optimal method of sample collection 
without effect on cytokine secretion, it was decided that fresh specimens should 
be collected where possible. Regulatory T cells were then enumerated (figure 
3.3) in patients with both malignant and non-malignant tumours with no 
difference between the groups being found. The second aim was to 
characterise the specific cytokine levels measureable in both serum and 
cerebro-spinal fluid (CSF) in both malignant and non-malignant glioma patients 
and identifying the source of the specific secretions. These experiments 
revealed a consistent difference between the groups in the levels of specific 
analytes in both serum and CSF. The levels were shown to respond to tumour 
removal and so the utility of measuring these secretions was revealed. 
Immunohistochemical analysis of tumour sections from these patients showed 
an increased production of the analytes within the tumour suggesting that the 
site of production is the tumour itself and not cells in the periphery. These 
analytes had a potential to act as specific biomarkers for these disorders and a 
panel of biomarkers was developed and tested for both low and high grade 
patient serum analysis with the ability to distinguish between low grade, high 
grade and non-cancerous sera. These panels gave sensitivities and 
specificities of up to 75% and 76%, respectively although these figures are 
related to the methodology employed in this analysis and may be different if 
another methodology were used.  
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The general discussion will now concentrate on a number of results including 
the lymphocyte viability study, the presence of Tregs in glioma, 
immunohistochemistry for follistatin, leptin, and PDGF, comparisons of 
potential biomarkers in serum and CSF and subsequently a new proposed 
diagnostic testing strategy.  
4.2 Lymphocyte viability study 
In this part of the study involving the effect of cryopreservation on lymphocyte 
viability it was shown that viability was significantly lower in the samples which 
had been cryopreserved than those which had been stored at 4°C, (table 3.3). 
These results were contradicted compared to some other reports (Buhl, et al. 
2012) but supported by others who showed a loss of T-cell function after long-
term cryopreservation (Owen, et al. 2007).   
Another interesting result of this study is the lack of negative correlation of 
viability with length of storage of the sample, (table 3.1). There was no decrease 
in viability despite the oldest sample being tested 13 days after collection. 
Interestingly however, this sample contained the highest concentration of TNF-
α, suggesting higher levels of apoptosis, which again was not consistent with 
the high percentage viability.  
The media added to samples can significantly alter cell viability. The addition of 
human AB serum demonstrates a reduced viability when compared with other 
sera. These researchers also found that the temperature of the washing media 
can influence the cell viability suggesting that the washing media should be 
warmed before use (Disis, et al. 2006).  
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TNF-α was chosen as a product of apoptosis and the increased secretion of 
which was potentially indicative of this process occurring (Sabri, et al. 2003). 
The patient with the highest concentration of TNF-α of 84 pg/ml, (table 3.5) was 
still within normal ranges of 75 pg/ml ± 15 (Damas, et al. 1989). The remaining 
samples had consistent levels of TNF-α of around 25 pg/ml within the normal 
range. This observation suggests that for these patients there was no increase 
in TNF-α in peripheral blood.  
4.3 Presence of Tregs in high and low grade gliomas 
The buffy coat samples used in this study were stored at -80°C without the use 
of cryopreservatives such as dimethylsulphoxide (DMSO). These were used as 
a concentrated source of white blood cells to be used in the analysis. This may 
have resulted in the excess cellular debris that was evident on the scatterplots 
from the flow cytometer, (figure 3.3). Gating was performed on the forward 
scatter-side scatter plot in the region that contained lymphocytes according to 
the manufacturer’s recommendations. Unstained cells were analysed and a 
degree of autofluorescence was detected which was reduced upon altering the 
gains and compensation values of the laser in the flow cytometer. There was 
also significant interference from other cell types and haemoglobin 
contamination making separation of the cell pellet difficult.  
In this current work, the mean percentage of CD4+CD25+FoxP3+ Tregs was 
determined in both glioblastoma and meningioma peripheral patient buffy coat 
samples. The results showed that the percentage of Tregs in GBM patients was 
slightly lower (1.72 ± 0.233%) when compared to meningioma patients (2.35 ± 
0.85%), (table 3.9). There was no significant difference between the two groups 
with p=0.418. Fecci, et al. (2006) reported a diminished fraction of 
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CD4+CD25+FoxP3+ Tregs in patients with malignant glioma but they further 
suggested that they also formed an increased percentage of the CD4 
compartment which was sufficient to cause the decreased T-cell function found 
in these patients. The lower proportion of Tregs in both malignant and non-
malignant tumours suggests that any role these cells may play is not connected 
to the degree of malignancy, angiogenesis and proliferation of these tumours.  
The present data show clearly a significant difference in the viability of cells 
from the fresh and frozen samples with significantly decreased lymphocyte 
viability observed after cryopreservation. The findings suggest that this method 
of cryopreservation may not be suitable for further experimental models, and 
that freshly isolated lymphocyte samples only should be used to detect secreted 
cytokines and apoptotic proteins.  Further research into the role of TNF-α as an 
apoptotic factor in lymphocytes would be beneficial (Bao and Cao 2014). 
 
The Treg enumeration experiment involved the transport of buffy coat samples 
from the BTNW tissue bank. Mallone, et al. (2011) indicated that transportation 
conditions can affect the quality and characteristics. Other researchers have 
suggested that specific alterations in the CD4+/CD8+ ratio and the secretion of 
PBMC cytokines are altered depending on the storage and transportations 
conditions whilst NK cell and B cell subsets retain their phenotype (Posevitz-
Fejfar, et al. 2014). There was little or no data in the literature concerning the 
use of buffy coat samples but the decision was taken to use them as a large 
number of samples could be transported in one trip in a polystyrene transport 
box with frozen ice packs to maintain a temperature of at least -20°C.  
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The samples collected showed a disparity in the age ranges for the two groups. 
The glioblastoma patients’ age ranges were from 58-85 years whilst the 
meningioma age ranges were from 24-71 years. Previous research studies 
have suggested that the Treg compartment increases with age (Garg, et al. 
2014) and so future studies should be age matched to improve the accuracy of 
the comparison. 
The method of thawing of the frozen buffy coat samples was investigated with 
two methods tested for the effect on cell viability, slow (at 4°C) and fast (at 
37°C), (tables 3.6 and 3.7). Cells that had been thawed slowly had a higher 
average viability (70.01%) than those that had been thawed quickly (55.64%). 
This was the reason for thawing at 4°C. However, the results show a wide 
variability of viabilities in the fast thawing method (8.8%-95%). This may be due 
to the prior treatment of the buffy coat samples at the Royal Preston hospital 
before they were collected.     
 
The cytokine analysis was performed on frozen serum samples received from 
the BTNW tissue bank stored at -80°C. These samples were transported to the 
research laboratories in polystyrene boxes with frozen ice packs inserted. They 
were transferred directly to the -80°C freezer upon arrival at UCLan, Preston, 
UK. Thawing took place at room temperature and once the samples had been 
aliquoted they were immediately snap frozen in liquid nitrogen.  
 
 
Patients affected by malignant gliomas in this study had, in most cases, higher 
pre-operative concentrations of analyte than the non-cancerous controls. The 
exceptions to this were IL-8 and Angiopoietin-2, (figure 3.5), in which the control 
group had a significantly higher concentration than the glioma group. Gliomas 
169 
 
produce angiogenesis factors in response to hypoxia while promoting neo-
angiogenesis and growth (Yano, et al. 2006). The patients in this study were 
taking dexamethasone (16 mg/day), which has been shown to downregulate 
the production of follistatin and PDGF-BB (Yano, et al. 2006). This observation 
makes the significant difference between the groups in these analytes even 
more compelling. 
The present study has shown the disrupted and sensitive response of cell-
mediated cytokine and angiogenesis related protein secretion in malignant 
glioma patients. It has also shown that there are a specific set of proteins that 
react to tumour removal.  
The luminex technique used is a reliable and reproducible technique that 
measures concentrations of multiple analytes simultaneously within four hours 
using only 50μl of sample and is clearly suitable for use in clinical practice. 
4.4 Immunohistochemistry – Follistatin 
Some gliomas exhibited follistatin immunostaining of tumour cells and many 
appeared to express gemistocytic morphology. However, staining was not 
uniform throughout the tumour sample and some cells were patently immuno-
negative, (Figure 3.6). Positive immunostaining was entirely cytoplasmic with 
no membrane or nuclear component and other tissue elements within the 
sections, including blood vessels, were completely negative (Figure 3.6 b). 
There were no specific features of the tumours or constituent cells which were 
evidently predictive of immunopositivity or to account for the significant 
variability between individual tumours. The non-cancerous (viz. normal) brain 
tissue, obtained from patient’s with non-malignant pathologies, was uniformly 
negative throughout and there was no staining of either neurones or glial cells 
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(Figure 3.6 c). There was a distinct interstitial stain in the presence of negatively 
staining cells that followed the axonal tracts of the sections (figures 3.6 d and 
e). There was no specific axonal staining and some of the axonal tracts did not 
take up any stain. The non-cancerous brain axonal tracts were uniformly 
negative (figure 3.6 f). There was some specific cytoplasmic staining of some 
cells from the choroid plexus (figure 3.6 g). This may suggest that follistatin is 
being secreted into the CSF and warrants further detailed CSF analysis of 
anigiogenesis-associated proteins.  
Vaquero, et al. (2000) reported that increased expression of angiogenic factors 
are a good predictor of transformation from low grade glioma to high grade. The 
imbalance between activin A levels and its inhibitor follistatin may influence the 
progression from low grade to high grade. Zhang, et al. (2010) reported 
increased expression of activin A whilst there was little difference in the 
expression of follistatin between low and high grade samples which suggest an 
inhibitory role for follistatin in the transformation from low to high grade glioma. 
The overwhelming up-regulation of activin A in high grade gliomas (Zhang et al. 
2010) is not sufficiently neutralised by the mediocre up regulation of follistatin 
and therefore its inhibitory effect is marginal. This hypothesis is supported in 
this work considering the results just discussed. 
4.5 Immunohistochemistry – Leptin 
The leptin immunohistochemistry showed some unanticipated results (figure 
3.7 and table 3.14). There was some small concentration of staining in the 
interstitial spaces of non-cancerous brain. This staining was not considered to 
be an experimentally-induced artefact as the staining was consistent with other 
positive sections. As glial cells and micro-vessels are the main sites of the ObR 
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receptor it is to be expected that in areas of tissue that contain a high proportion 
of these, leptin is present. Conversely there were also some areas of negativity 
in the high grade glioma sections. The heterogeneous nature of glioma could 
indicate a clone of non-malignant cells interspersed within the tumour or cells 
that have newly differentiated and have not yet started to produce leptin. 
The present results have shown that leptin was expressed at a low 
concentration (+) in the interstitial space of non-cancerous tissue but at higher 
concentrations in both the interstitial space and the cytoplasm in both low and 
high grade gliomas. Leptin was rarely located in the nucleus in both non-
cancerous and glioma specimens, only producing a (+) stain in the highly 
malignant gliomas. These data are in contrast to those of Morash, et al. (2000) 
who localised leptin to the nucleus of C6 cells. Morash, et al. (2000) further 
stated that the data collected in their study suggested the presence of nuclear 
binding of leptin and that RT-PCR analysis using primers specific for OBRs 
(short form) and OBRb (long form) indicated that C6 cells can only express the 
short leptin receptor isoform.  
These results show that the greatest staining of leptin by tumour cells is in the 
cytoplasm and that for each of the analysed areas (nucleus, interstitial space 
and cytoplasm) the staining intensity of leptin increased in correlation to the 
degree of malignancy. 
4.6 Immunohistochemistry – Prolactin 
The mediocre immuno-histochemical staining of prolactin in this study does not 
distinguish between endogenous, extra-pituitary prolactin and prolactin 
captured by prolactin receptors and tumour resection of the source of 
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production of the increased prolactin, (figure 3.8). These results are insufficient 
as an explanation for the post-operative decrease. 
The studies of Soares et al. (2007) have supported the finding of increased 
serum prolactin. However the present study demonstrated 86% 
hyperprolactinaemia in glioblastoma patients and 75% in low grade glioma 
patients. These data must be examined in the light of the glioma patient’s 
treatment regime. Other researchers have reported that anti-epileptic drugs 
may modulate hormone release from the hypothalamic-pituitary-gonadal axis 
and they may alter the metabolism of sex hormones and their binding proteins 
(Verrotti, et al. 2009). Clearly a patient’s full drug history, not currently available, 
must be accounted for when reviewing these results but the abrupt decrease 
within twenty-four hours of tumour de-bulking suggests a tumour-based 
influence upon prolactin production.   
4.7 Immunohistochemistry – PDGF 
Aberrant PDGF signaling is known to play an important biochemical and 
physiological role in glioma cell transformation from multipotent neural cell 
progenitors (Calzolari and Malatesta 2010). Increased PDGFRα expression is 
linked with a loss of heterozygosity on chromosome 17p in the region of the 
tumour suppressor gene TP53 which signals a possible effect on PDGFRα 
expression (Hermanson, et al. 1996). Hermanson et al. (1996) further 
suggested that over-expression of PDGFRα could contribute to tumour cell 
proliferation in the early and late stages of glioma development. Staining of low 
grade biopsies for the PDGFRα moiety should be undertaken to confirm this. 
(Martinho, et al. 2009) reported increased expression of PDGF-AA in 81.2% of 
160 glioma biopsies. However, this does not confirm a correlation with PDGFRα 
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expression in contrast to this study in which the correlation was admittedly weak 
(r=0.5). There is sufficient support, however, for significant over-expression of 
the PDGF-AA ligand in glioma stem cells (Zhang, et al. 2015).  
Semenza (2013) reported that hypoxic conditions could induce the production 
of hypoxia-inducible factors (HIFs) of which PDGF-BB is one. However (Costa, 
et al. 2012) demonstrated a role for PDGF-BB in the downregulation of 
microRNAs miR-21 and miR128 which was associated with increased cell 
proliferation. The increased expression of PDGFRα, PDGF-AA and PDGF-BB 
in this study, (figure 3.9 and table 3.15), suggests an autocrine and paracrine 
function for these molecules in cellular proliferation and tumourigenesis.  
 The decreased expression of PDGFRβ is in contrast to previous studies that 
noted an increased expression (Li and Xu 2016b). However, Brennan, et al. 
(2009) have postulated a link between an increase in PDGFRα expression and 
a decrease in PDGFRβ. This is supported by the data of the present study as 
there was only a single patient sample with an increased PDGFRβ expression 
and this was matched with a further increased PDGFRα expression. There was 
only a single staining of a non-cancerous control for PDGFRβ and further 
staining of non-cancerous samples would be beneficial in confirming the under 
expression in high grade glioma. 
PDGFRα and PDGF-AA ligand expression displayed a significant positive 
correlation (r=0.5), (table 3.15). The present results could suggest that increased 
expression of PDGFRα could upregulate expression of the PDGF-AA ligand or 
vice-versa. If this is the case then an autocrine role in the promotion of cellular 
proliferation should be considered for these molecules (Venugopal, Wang et al. 
2012). They showed that neural precursor cells exposed to GBM conditioned 
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media become highly proliferative and display an increased expression of growth 
factor receptors such as PDGFRα. This was augmented by an increased level of 
PDGF-AA in the GBM conditioned media. Further investigation into a possible 
autocrine activity for PDGFRα and PDGF-AA is warranted including an 
investigation of which molecule stimulates the upregulation of the other. 
In addition, the present results show a significant correlation between PDGF-AA 
serum concentration (pg/ml) and PDGF- BB ligand expression in Primary GBM 
(r=0.89). Shure, et al. (1992) show that PDGF AA is a strong chemoattractant for 
human monocytes, granulocytes, and fibroblasts. Therefore, PDGF-AA elevation 
in glioma, can be attributed to the altered glioma immune environment. 
Interestingly, Zheng, et al. (2016) reported the link between the overexpression 
of PDGF-BB in glioblastoma and the recruitment of oligodendrocyte precursors 
expressing increased levels of PDGFRα which in turn lead to increased 
expression of PDGF-AA. 
The interactions of the PDGF family of molecules in driving glioma cell 
proliferation is a complex and multi-layered process that may include several 
redundant and pleiotropic mechanisms. There are many methodological 
limitations that can compromise these results. 
 This work aimed to locate the source of PDGF receptor and ligand 
expression in high grade glioma and to examine any possible correlation 
with systemic concentrations. Of 18 high grade tissue sections PDGFRα 
had increased expression in 93.75% of specimens, PDGF-BB was 
increased in 75% and PDGF-AA in 43.75%. PDGFRβ had 25% of 
specimens showing increased expression and 56.25% decreased 
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expression. All sections were compared to non-cancerous control 
specimens.  
  These results suggest that PDGFRα/PDGF-AA signaling could lead to 
increased angiogenesis in addition to that due to oxygen requirement from 
hypoxic tissue. This stimulus would lead to an induction of hypoxia-
dependent production of PDGF-BB which leads to an increased 
chemotactic response of peripheral immune cells which, in turn, 
contributes to an immunosuppressive micro-environment. 
  Immunohistochemistry does not reveal the source of the proteins only the 
location within the tissue therefore speculation on biological function is 
compromised. Staining intensity scoring is subjective and the ELISA 
method of serum analysis has low sensitivity. There was also a limited 
sample size of 6 patients due to availability of matched tissue and serum 
samples in which the correlations were calculated. A larger cohort would 
provide greater accuracy in this comparison. 
4.8 Discussion of potential biomarkers 
The platform of the serum analysis was based on a luminex technology and 
was performed on the Bio-Plex 200 analyser. This platform utilises many micro-
beads coated with antibody of the analytes tested. The technique includes 
many washing steps for which a wash station was used. This automated 
method is preferred over the manual washing method and increases both 
reliability and reproducibility. The inherent variation induced by the operator’s 
technique is thus minimised. The automated cell washer was validated before 
the assays were performed according to the manufacturer’s instructions. (Bio-
rad 2013) The mean percentage recovery of the beads was consistent with the 
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manufacturer’s guidelines at 91% recovery. The process of testing the analytes 
takes somewhere around 4 hours with this technology. This could be improved 
in a clinical laboratory setting with a more automated version of the luminex 
analyser. Other potential methodologies to measure the analytes include mass 
spectrometry and chip technology. Both of these methods are considerably 
more expensive than the luminex technique used in this study. There was no 
correlation with any of the potential biomarkers and survival or gender, (table 
3.21). This was not surprising due to the heterogeneity of the tumour and the 
many factors influencing the production of the analytes in question. A more 
detailed longitudinal study of the analytes from patients could provide more 
prognostic information for instance the likelihood of tumour recurrence following 
removal. 
The increased levels of some analytes in the CSF mirrored those within the 
serum (figures 3.10 and 3.12). This is an interesting finding that warrants further 
investigation although it should be noted that CSF is a more intrusive fluid to 
obtain for diagnosis compared with blood serum. 
Prolactin has been traditionally associated with mammary development and 
lactation although, more recently, several studies have implicated the hormone 
in tumourigenesis through disruption of the JAK-STAT pathway (Gorvin 2015). 
These studies are restricted to breast cancer, however the role of prolactin and 
its receptor in glioblastoma is being elucidated. Other studies have detected the 
presence of intracellular prolactin, prolactin receptor (PRL-R) and 
hyperprolactinemia in different types of central nervous system (CNS) tumours. 
Ciccarelli, et al. 2001; Van Meir et al. 1990 discovered the presence of PRL-R 
and hyperprolactinemia in 45.4% and 27.2% of meningiomas and 69.2% and 
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61.5% of schwannomas respectively. In these studies the level of the receptor 
and the ligand were not correlated. Soares et al. (2007) discovered the 
presence of PRL-R in 39% of patients with CNS tumours and the presence of 
intracellular prolactin in 21.9% of those patients. There was also 
hyperprolactinaemia in 30% of 82 cases. Their data suggested a positive 
correlation with serum prolactin and intracellular prolactin. Both of these studies 
confirm the data obtained in the present study of increased serum prolactin 
however the present study demonstrated 86% hyperprolactinaemia in 
glioblastoma patients and 75% in low grade glioma patients.  
These data must be examined in the light of the glioma patient’s treatment 
regime. Some researchers have reported that anti-epileptic drugs may 
modulate hormone release from the hypothalamic-pituitary-gonadal axis and 
they may alter the metabolism of sex hormones and their binding proteins 
(Verrotti, D'Egidio et al. 2009). Clearly, a patient’s full drug history must be 
accounted for when reviewing these results but the abrupt decrease within 
twenty-four hours of tumour de-bulking suggests a tumour-based influence 
upon prolactin production. The mediocre immuno-histochemical staining of 
prolactin in high grade tissue samples discussed in chapter 4 does not 
distinguish between endogenous, extra-pituitary prolactin and prolactin 
captured by prolactin receptors and tumour resection of the source of 
production of the increased prolactin is insufficient as an explanation for the 
post-operative decrease.  
Granulocyte colony stimulating factor (G-CSF) is a cytokine in routine use in 
cancer treatment which enables haemopoietic rescue following chemotherapy 
and radiotherapy. This cytokine also has a dual role in stimulating both immune-
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suppression and tumour mediated angiogenesis in glioma (Aliper, et al. 2014 
;Wang, et al. 2012). This has resulted in the limitation of its use to prevent the 
iatrogenic induction of tumour growth.  
Soluble human epidermal growth factor receptor 2 (sHER2-neu) is a circulating 
biomarker using in monitoring treatment efficacy in breast cancer (Stieber, et 
al. 2011). (Kostler, Steger et al. 2004) reported that breast cancer patients with 
decreasing sHER2-neu levels 30 days post-treatment with trastuzumab and 
chemotherapy showed a greater response to the treatment given. The 
decreased sHER2-neu levels in the glioma patients, shown in the present 
study, may be a reflection of the treatment regime of the patients in the study. 
Whilst the treatment for glioma does not intentionally target sHER2-neu, this 
could be an effect of the chemotherapy given to the high grade glioma patients. 
Interleukin-6-mediated activation of Stat3 is a principal pathway controlling 
tumourigenesis (Sansone and Bromberg 2012). This transcription factor has a 
role in the regulation of specific mediators of tumour progression and is a 
promising therapeutic target (Roxburgh and McMillan 2016). The present study 
shows an increase in the soluble IL-6 receptor in high grade gliomas which may 
be a reflection of the increased mediation of the STAT pathway in tumour cell 
propagation. 
 The components of the plasminogen-plasmin system of fibrinolysis have been 
associated with increased cell migration and proliferation. These include uPA, 
uPAR and their inhibitor PAI-1 and (McMahon and Kwaan 2015) have noted 
utility in the prognostic information received with regard to numerous cancers 
including glioma. uPA is also the subject of a targeted therapy with authors 
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reporting inhibition of glioma cell migration  through inhibition of the uPA 
molecule itself (Chou, et al. 2015). With the significant increase of this marker 
noted in this study, there is a pattern emerging of an angiogenetic panel of 
markers within the field of potential diagnostic biomarkers for glioma. 
The distinction between high and low grade gliomas relies on the fact that high 
grade gliomas are malignant and invasive and therefore have a higher rate of 
angiogenesis. Several of the potential biomarkers have been associated with 
increased cell migration and proliferation of glioma cells in vitro (Becker, et al. 
2010;Lee, et al. 2014). Anti-angiogenic therapies are being explored as 
treatment strategies in clinical trials. Chae, et al. (2010), demonstrated a 
complex interaction of expression of some of the potential biomarkers 
(sVEGFR-1) in response to drug therapies and a detailed history of the 
participant’s treatment regime may be necessary to fully elucidate the 
expression pattern of the potential biomarkers in the individual patient. More 
recent trials have been unsuccessful however (Chowdhary and Chamberlain, 
2013). 
Hypoxia-induced angiogenesis is one of the key models for the cause of 
microvasculature with GBM. Tumour cells that outgrow endogenous blood 
supply undergo hypoxia, mediated by HIF-1α transcription, leading to the 
transcription of angiogenic factors, vascular endothelial growth factor (VEGF-
A), platelet-derived growth factor ligand BB (PDGF-BB) and follistatin, (Charles, 
et al. 2012b). The tumour therefore mediates its own progression through 
healthy tissue in creating the angiogenic factors neccessary for the formation 
of new blood vessels. As surgery reduces the hypoxic area of the tumour, the 
stimulus for such production is also reduced. Therefore a further potential cause 
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for the drop in Follistatin concentration in postoperative patients could be the 
reduced hypoxic drive of the tumour following debulking surgery.  
The platelet-derived growth factor receptor beta (PDGFRβ) has been noted on 
tumour vasculature cells (Li and Xu 2016b) and as PDGF-BB can signal 
through all PDGF receptors. It is a promising ligand to drive tumour progression, 
and has been noted to upregulate the production of VEGF-A – an important 
angiogenic factor (Xue,  et al. 2013). The present study measured serum levels 
of PDGF AB BB only and a clearer elucidation of the different individual 
isoforms of PDGF (AA, AB and BB) and their receptors is required to resolve 
the contribution of these to the increase in serum levels of PDGF and VEGF-A. 
The role of cell adhesion molecules in glioma angiogenesis and invasion has 
also been documented (Burim, et al. 2009). Whilst the present study included 
PECAM-1 only, the work of Burim et al. (2009) suggests that polymorphic 
variants of ICAM-1 are correlated with diffuse Grade II astrocytomas.  
VEGF-A is a key mediator of angiogenesis, increasing in serum levels 
proportionally to the vascularity of gliomas, and complexes with sVEGFR-1 
reducing its bioavailablity (Lamszus, et al. 2003). Lamszus et al. (2003) suggest 
that whilst sVEGFR-1 is increased in glioblastoma, in agreement with the 
present study, the sVEGFR-1: VEGF-A ratio is decreased in these more 
malignant gliomas thereby increasing the bioavailability of VEGF-A and hence 
an increase in angiogenesis. The usefulness of sVEGFR-1 as a potential 
biomarker would therefore be linked to VEGF-A levels in an individual patient.  
The tumour microenvironment is pro-angiogenic and it is composed of cancer 
cells, stromal cells and immune cells including cancer-associated fibroblasts. 
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Interestingly (Katoh 2016) reported an increased efficacy of fibroblast growth 
factor (FGF) inhibition when combined with VEGF inhibition in producing anti-
tumour effects in cultured cells. Serum FGF levels have been shown to be 
elevated in both oesophageal and lung cancers (Keeley, et al. 2014). Keeley et 
al. (2014) reported that FGF levels were elevated up to two years before 
diagnosis of such cancers.  
There is a convincing correlation between the levels of potential biomarkers in 
this study with increased levels of malignancy and therefore angiogenesis 
(Pang, et al. 2012; Majumdar, et al. 2009).  
The significant changes of three potential biomarkers, follistatin, G-CSF and 
prolactin after de-bulking, (figure 3.13), led to Lekka et al. (2015) suggesting 
that these have potential for use in monitoring patient treatment. These data 
support the hypothesis of the tumour being the source of some of the potential 
biomarkers. 
4.9  Discussion of novel diagnostic testing strategy 
The data obtained in the present study suggest that panels of multiple 
biomarkers should be considered for diagnostic use and an orthogonal testing 
regime be formulated (table 4.1). The potential biomarkers would need to 
undergo rigorous testing in the confirmation, assay development and validation 
stages of biomarker approval before a reference range could be produced. 
The first panel should consist of those biomarkers with the greatest power to 
distinguish tumour from non-cancerous serum as well as the ones that show a 
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decrease upon tumour removal. A secondary panel of biomarkers should then 
be tested to distinguish grade of tumour. (Table 4.1a and 4.1b). 
Table 4.1.  A prospective diagnostic testing pathway to distinguish between 
low grade and high grade glioma from non-cancerous serum. 
a) 
 
b) 
 
The studies performed have shown differences in the means of the glioma and 
non-cancerous samples. To generate a putative cut-off point the following 
procedure was used. A 95% confidence interval was used to calculate a normal 
reference range with the non-cancerous sera. An increase or decrease of 2 SD 
in the cancerous cohort was used to calculate a positive diagnostic level of the 
biomarker. The average number of positive biomarkers in the 115 high grade 
patients was 3.79, for the 44 low grade patients it was 3.56. The non-cancerous 
Panel 1
Expected 
result for HGG 
sera
Expected 
result for 
LGG sera
Expected result 
for non-cancerous 
sera
Prolactin Increased Increased Normal range
sVEGFr-1 Increased Increased Normal range
FGF-basic Increased Increased Normal range
Follistatin Increased Increased Normal range
G-CSF Increased Increased Normal range
sHER2-Neu Decreased Decreased Normal range
Panel 2
Expected 
result for HGG
sera
Expected 
result for
LGG sera
Expected result
for non-cancerous
sera
sIL-6R alpha Increased Normal range Normal range
uPA Decreased Normal range Normal range
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patients were falsely positive in 1.56 biomarkers. The sensitivities and 
specificities of using different numbers of positive biomarkers to confirm 
diagnosis in panel 1 is given in table 4.2. These results were calculated by 
looking at each individual glioma patient and assessing how many of the stated 
biomarkers they were positive for. Therefore, 100% of high and low grade 
glioma patients were positive in at least one of the biomarkers giving a 
sensitivity of 100% however 75% of the non-cancerous cohort were also 
positive in one of the biomarkers hence there is a specificity of 25% using only 
one biomarker. The optimum number of positive biomarkers in panel 1 to aid 
diagnosis would be 2 although using 3 would significantly reduce the numbers 
of false positives by 12%. 
Table 4.2. Sensitivity and specificity of panel 1 compared with the number of 
positive biomarkers used. 
 
Table 4.3 shows the sensitivities and specificities for using 1 or 2 biomarkers to 
distinguish between low and high grade glioma. There is a trade-off between 
sensitivity and specificity depending on the number of biomarkers used. 
Discovery of more biomarkers to distinguish between the grades would allow 
for greater resolution of glioma grade using panel 2. The differences in serum 
No. of positive 
biomarkers 
Sensitivity  for 
high grade
Sensitivity 
for low grade
Specificity
1 100% 100% 25%
2 94% 89% 64%
3 75% 73% 76%
4 56% 55% 85%
5 43% 30% 94%
6 11% 7% 100%
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concentration between cancerous and non-cancerous sera for sIL-6R alpha 
and uPA given in figure 3.10 were significant albeit only at the p<0.05 level. 
Therefore this lower significance level contributes to the resultant lower 
sensitivities found in panel 2. 
Table 4.3.  The sensitivity and specificity of panel 2 compared with the 
number of positive biomarkers used. 
 
4.10 Scope for future studies 
The cryopreservation of samples presented some technical problems that may 
have had an adverse impact on the accuracy of the results obtained. Future 
experiments should use fresh blood and a density gradient medium to separate 
peripheral blood mononuclear cells (PBMCs) as suggested by other 
researchers to reduce the non-specific staining causing autofluorescence 
(Mallone, et al. 2011). A more accurate method of assessing cellular viability 
using propidium Iodide in a flow cytometric method rather than the manual 
method of the trypan blue assay would have been useful although both trypan 
blue and propidium iodide assays are limited as these assays only represent 
the intactness of the cells and have little relation to the functionality of the cells. 
The effect of cryopreservation would be better assessed by the testing of fresh 
samples and then re-testing the samples after specific periods of time to see if 
there is any decrease in viability and a change in the production of TNF-α.   
No. of positive 
biomarkers
Sensitivity  for 
high grade
Sensitivity 
for low grade
Specificity for high 
grade
1 90% 84% 27%
2 38% 27% 85%
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The present study took no account of circadian rhythms of cytokine secretion 
and a log of the time of day the sample was taken was not performed. Likewise 
there was no data relating to patient age and gender taken with the samples 
and so any effect from these factors was ignored. Further study should be done 
to evaluate the correlation of other demographic metrics such as age, drug 
therapy and gender with TNF-α. 
The experiment that compared the presence of Tregs between glioma and 
meningioma would have been better served by including a non-cancerous 
cohort. The low serum levels of Treg cells in malignant and non-malignant 
tumours may be due to the fact that Tregs migrate towards the site of the tumour 
and be embedded within the tissue. Further work should be performed to find 
evidence of tumour infiltration of the Treg compartment as well as comparing 
serum levels between tumour and non-cancerous patients. 
Lastly, TNF-α was chosen as the cytokine to measure in this experiment due to 
its influence on the induction of apoptosis with higher levels indicating an 
increased number of cells undergoing apoptosis. However the induction of 
apoptosis is a complex process involving other receptors and the production of 
TNF-α by other cell types such as macrophages, monocytes and fibrinoblasts 
(Bao and Cao 2014). The present study provides only a crude snapshot of the 
process which may explain the lack of difference in most of the patient levels 
following cryopreservation and further research into the role of TNF-α as an 
apoptotic factor in lymphocytes would be beneficial. 
The immunohistochemical staining of leptin revealed the localisation of leptin 
did not occur in the nucleus. However Morash, et al. (2000) revealed different 
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forms of the leptin receptor in C6 cell lines and other researchers demonstrate 
that only the short form receptor has leptin-dependent signalling potential 
(Bjorbaek, et al. 1997). Its presence suggests an autocrine function for leptin in 
glioma tissue. As the present study used primary tissue RT-PCR analysis of 
primary glioma tissue should be investigated to see if the results of Morash et. 
al (2000) in a glioma cell line can be replicated in primary tissue and therefore 
the production of leptin in glioma patients can be re-evaluated. 
The distribution of the OBr receptor may influence the localisation of the leptin 
ligand and so future studies should indicate the precise location and amount of 
leptin receptors in non-malignant tissue to enable a more meaningful 
comparison with leptin distribution in malignant tissue. 
Likewise, the inability of the prolactin staining to distinguish between 
endogenous secretion and prolactin captured by prolactin receptors prevents 
an informed discussion of the stark decrease in serum levels following 
resection. Further investigation of the presence of the prolactin receptor (PRLR) 
in both non-cancerous and glioma tissue would demonstrate whether the 
receptor is saturated with extra-pituitary prolactin ligand in glioma patients. This 
study should be corroborated by mRNA extraction coding for prolactin to 
elucidate further the source of the increased serum levels. 
The immunohistochemical analysis of PDGF ligands and receptors revealed a 
complex interaction between PDGFRα and PDGF-AA signalling that may lead 
to increased angiogenesis and a hypoxia-dependent production of PDGF-BB. 
Future study should look at the molecular interactions of the PDGF family of 
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ligands and receptors with regards to a therapeutic strategy of disruption or 
blocking of these interactions to prevent or reduce angiogenesis. 
Some cancer-specific treatment modalities warrant the use of haemopoietic 
rescue following a chemotherapeutic regime using G-CSF as a stimulator of 
haemopoietic stem cells. Clearly, the increase in serum levels of G-CSF shown 
in this study suggests that an investigation into the precise role of G-CSF in 
glioma production is required in order to determine treatment efficacy as well 
as to contribute to unravelling the source of the post-operative reduction in G-
CSF levels. Another potentially artificially-induced analyte increase is in the 
soluble IL-6 receptor. Whether this is tumour-produced or as a result of an 
inflammatory response to the malignancy is a subject of further investigation 
involving a non-cancerous patient cohort with an inflammatory condition. 
Some of the candidate biomarkers discussed in this study are being considered 
as potential markers for other potential targets. Some of these are polymorphic 
variants of the markers already discussed that may be more responsive to 
glioma progression. ICAM-1 is a further candidate for a potential biomarker to 
investigate with regard to low-grade glioma progression to more malignant 
grades. Other biomarkers such as VEGF A and its interaction with its receptor 
display a dynamic change during glioma progression. Further study is required 
to determine the dynamics of the sVEGFR-1: VEGF-A ratio from progression 
towards malignant forms of glioma. This ratio may be a more specific and 
therefore more revealing metric in disease monitoring. Also a historical 
perspective may also be necessary as FGF levels may be artificially increased 
a considerable time before the earliest diagnosis. The present study suggests 
an elevation in the serum levels of FGF in glioma patients however there may 
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be evidence to warrant an investigation into pre-diagnosis samples if they could 
be obtained. 
Angiogenesis, as one of the hallmarks of cancer, leaves a footprint with the 
potential biomarkers in this study however the scale of correlation with the 
amount of angiogenesis taking place remains unknown. Measurements of 
vascularisation in individual patient’s tumour sections should be undertaken to 
investigate any possible correlation with serum levels of the biomarkers. 
Many of the significant serum analytes also displayed an increase in CSF 
samples albeit from only 8 samples available suggesting that the source of 
production of some of the potential biomarkers has access to both the 
bloodstream and CSF. This points towards the tumour itself as the site of 
production of the analyte although more samples would be needed to verify this 
in a future study. Future work would include a longitudinal study.  
In this future study there will be an investigation of a comprehensive panel of 
blood-borne biomarkers that potentially may have predictive or prognostic 
significance in a large series of glioblastoma patients recruited from the two 
major treatment centres in the North West.  In addition longitudinal biomarker 
studies will be undertaken in patients treated with combined temozolomide and 
radiotherapy to assess the relationship of markers with tumour burden, 
response to therapy and progression. The prognostic significance of T 
lymphocyte populations will also be assessed. 
Adult patients of age greater than18 years, will be recruited prospectively at the 
Walton Centre / Clatterbridge Centre for Oncology and the Royal Preston 
Hospital and all patients with glioblastoma who give consent for research will 
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be included in the study irrespective of their performance status and clinical 
management. The aim is to recruit 250 patients overall. Patients with newly 
diagnosed glioblastomas as well as those with an earlier lower grade tumour 
will be included. Longitudinal investigations of biomarkers in comparison to 
imaging and outcome will be undertaken for good performance patients treated 
with concurrent and adjuvant temozolomide and radiotherapy.  Based on 
current clinical practice approximately 80 patients would be available for this 
part of the study. 
Blood samples will be obtained at initial diagnosis pre-surgery for all patients 
and at defined stages during the clinical: - at initial diagnosis, 24 hours post-
surgery, pre-therapy; after radiotherapy [prior to adjuvant therapy]; after 
adjuvant therapy; at 3 months then 6 monthly post therapy; at recurrence or 
suspected recurrence, and at intervals during further therapy and follow up as 
long as practical depending on the individual patient. Blood samples will be 
taken as close as possible to neuroradiology investigations. Tumour tissue 
samples from further surgeries would be stored for comparative studies.   Blood 
samples will be collected and processed according to a standard protocol used 
in both hospitals to generate serum, plasma and cellular fractions. 
Tumours will be diagnosed according to WHO criteria. For research purposes, 
independent histopathology re-review will be undertaken by the consultant 
neuropathologists at each hospital and features such as histopathological 
phenotype, lymphocyte and T- cell infiltration, characteristics of the vasculature, 
extent of apoptosis and necrosis will be assessed. 
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Clinical data should be collated prospectively and will include details of therapy 
(dose, times), documented progression date and whether radiological, clinical 
or both, steroid doses at the intervals when blood samples are taken, 
progression free survival, details of further surgery or therapy and overall 
survival. MR and CT scans taken for diagnosis and at all stages of clinical 
management will be compared with biomarkers and volumetric assessment 
used to assess the relationship between markers and tumour burden.  Scans 
will be used to monitor therapy response or disease progression or suspected 
pseudo progression. 
Protein biomarkers present in serum or plasma will be measured and pre-
surgery, pre-therapy levels in glioblastoma patients (n=100) compared with 
normal healthy volunteers (n=50) and gliomas WHO grades II (n=50) and III 
(n=30).  For markers significantly deregulated in glioblastoma, comparison of 
expression in different molecular subtypes of glioblastoma will be made with 
outcome and with expression levels in tumour tissue. Biomarkers in longitudinal 
samples from patients treated with temozolomide and radiotherapy will be 
compared with therapeutic response assessed using the ‘response 
assessment in neuro-oncology’ (RANO) criteria used clinically for measuring a 
patient’s response to radiotherapy, and volumetric measures of tumour size 
using  T1+ gadolinium and T2 MR at discrete stages following  therapy and at 
recurrence.   
Diagnostic archival samples and snap frozen tumour tissues taken as part of 
planned surgery and surplus to diagnostic requirements will be available for 
each case for molecular classification (MGMT methylation and IDH1 mutation 
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status) and for comparison of biomarkers in blood with expression in tumour 
tissues.  
4.11 Conclusion 
A biomarker with high sensitivity and specificity to aid glioma diagnosis would 
be of great clinical utility. Current methods of diagnosis are invasive with the 
diagnostic test requiring hospitalisation. A rapid test based upon blood serum 
and would allow for a relatively non-invasive test and open up the possibility of 
screening for glioma as well as effective treatment monitoring and prediction of 
tumour recurrence. Analysis of the source of the proteins may reveal 
information regarding the mechanism of immunosuppression in these tumours. 
The present work has demonstrated the ability and potential of specific 
biomarkers to aid diagnosis of glioma in a patient’s blood sample. The diagnosis 
can be rapidly applied to the clinical environment allowing the possibility of 
screening of patients with equivocal symptoms of glioma upon first presentation 
which would be of great benefit to the clinician in improving patient outcome.  
This work studied both high and low grade glioma patients using serum, buffy 
coat and tissue samples supplied from the Brain Tumour North West research 
cluster under their ethical procedures. The studies were age and sex matched 
as much as possible. The main finding from these studies were as follows; 
General anaesthetic does not affect the levels of biomarkers therefore the 
differences are most probably disease-based. 
Tumour resection reduces some biomarker levels, suggesting a tumour cell 
source of some of the potential biomarkers. 
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Diagnostic information cannot be based on a single biomarker but a panel of 
biomarkers can be developed to distinguish between both high and low grade 
tumour patients and non-canceropus controls. 
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Appendix A 
 
Analytes female mean 
pg/ml / sd 
male mean 
pg/ml /sd 
n female n male 
     
     
Prolactin 28707 / 43389 21159 / 17091 88 133 
     
sVEGFr-1 867.5 / 309 922.4 / 329 88 133 
     
FGF - basic 206.9 / 60 214.6 / 60 88 133 
     
Follistatin 1847.4 / 700 1934.5 / 736 88 133 
     
G-CSF 468.6 / 417 497.7 / 473 88 133 
     
sHER2-Neu 3607.5 / 1545 3881.5 / 1524 88 133 
     
sIL-6R alpha 10732 / 5172 11297 / 5112 88 133 
     
PECAM-1 4805 / 1445 4914 / 1480 88 133 
     
uPA 232.7 / 63.2 253.7 / 87.8 88 133 
     
PDGF- 
ABBB 
7789.5 / 3158 8213.7 / 3537 88 133 
     
   
